[{"article": "Thanks to members Drs.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\n\u201cWe do not treat groups of people we treat individuals,\u201d said Dr. Thomas Trojian, Lead Author and Past AMSSM Board of Director.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The viscosupplementation procedure may be available at many clinics nationwide. We don\u2019t know so we are rating this Not Satisfactory. To be complete the release could have also noted that insurers place some important restrictions for payment and that\u00a0 Medicare coverage may vary among states.", "answer": 0}, {"article": "Dec. 6, 2010 -- Taking aspirin over a long period of time can substantially cut the risk of dying from a variety of cancers, according to a study showing that the benefit is independent of dose, gender, or smoking.\nThe latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\nAfter five years, death rates were shown to fall by 34% for all cancers and by 54% for gastrointestinal cancers.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe protective effect of taking low doses of aspirin varied according to the type of cancer and how long aspirin had been taken, the authors found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that aspirin has been widely recommended for cardiovascular benefits.", "answer": 1}, {"article": "Thursday's discussion focused on its use in preventing HPV-related disease in girls and women, including those as young as 9.\n\"We would like to see the FDA mandate some sort of labeling or other mechanism to communicate to health care providers and patients the continued need for regular cervical screening,\" said Amy Allina, program director of the National Women's Health Network.\nThe committee's HPV vaccine workgroup is recommending the vaccine be given to girls 11 and 12, and the committee will consider recommendations for females 13 to 26.\nThe anticipated cost of the vaccine, administered in three shots over six months, is $300 to $500, a possible impediment to widespread vaccination campaigns.\nAdvocates are recommending the vaccine be given to 11- and 12-year-old girls before they become sexually active, but argue that it is not a license to behave promiscuously, Kaledin reports.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story treats the FDA approval as fait accompli. Although the FDA usually goes along with what the panel recommends, approval may not be automatic or occur when reported.", "answer": 0}, {"article": "Our two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nFor expert advice:Consult a dermatologist.\nCreams must also be applied.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nA natural fern extract used by indigenous people \"for centuries,\" its promotional materials say, it's taken orally.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0It seems clear that the product is available and being actively promoted.", "answer": 1}, {"article": "Alexander Technique is a series of posture lessons, devised by a 19th century Australian actor named F.M.\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\n\"We look at what you are doing that causes that problem in the first place, so how you sit at the computer or how you pick up your child or what you do when you're driving,\" says Gray.\n\"The whole point is that you understand the process so that you can arrive there yourself,\" says Gray.\n\"It's a feeling of working with yourself from the inside out,\" says Rodriguez.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In a major oversight, the article didn\u2019t mention that instruction in the Alexander Technique is not widely available in the United States. And that insurance companies in the U.S. generally do not provide reimbursement for this therapy.\n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story contained estimates of how many people are currently taking statin medication.", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story does not report that this trial tested a specific type of exercise program known as Jaques-Dalcroze eurhythmics, so readers have no way of finding out whether it is available to them.", "answer": 0}, {"article": "Nov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\nIn a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\nIn people with osteoarthritis, the cartilage in a joint wears away in some areas.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that strontium ranelate\u00a0is available as a prescription drug for osteoporosis in some other countries, but is not approved in the U.S.\u00a0It explains that other strontium formulations\u00a0are available as nutritional supplements in the U.S., but that these might not work the same way that the strontium drug tested in the study works.", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discussed several approaches to treatment. \u00a0It focused on liver transplantation and indicated that livers were in short supply. \u00a0It indicated that weight loss was a means to stop progression of the condition and may be an adequate approach. \u00a0It also mentioned that there are a number of clinical trials being conducted for treatment of cirrhosis.", "answer": 1}, {"article": "The study was published online June 27 in The Lancet.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nAlthough the effectiveness of the drugs were similar, the study showed the side effects of linagliptin were much less severe than those of glimepiride.\nThe researchers found that 7 percent of patients on linagliptin experienced hypoglycemia, compared to 38 percent of patients treated with glimepiride.\nThe study, which was funded by linagliptin's maker, Boehringer Ingelheim, involved 1,500 people from 16 countries with type 2 diabetes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the story whether this drug is available anywhere. You could interpret the story both ways. \u201cThe study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness. They added more research is needed to confirm their findings.\u201d", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says \u201cMerck is expecting the FDA to approve Januvia by mid-October. The company has also submitted an application for a single tablet combination of Januvia and metformin, known as MK-0431a. The FDA is expected to make a decision on that drug by the end of March 2007.\u201d On the first statement, the story should not simply take the word of Merck on the date of \u2013 or the certainty of \u2013 expected FDA approval. And on the second statement, the story doesn\u2019t say who expects the FDA approval of the second drug. Who said that? Who\u2019s the source? ", "answer": 0}, {"article": "Those T-cells pick up melanoma cells\u2019 molecular scent and hunt them down before going off in search of tumor cells hiding elsewhere in the body.\n\u201cThe field is exploding, and this would be another arrow in the quiver that oncologists use.\u201d\n\nImlygic is part of a new group of immune-stimulating viral therapies that could change how cancer is treated and managed.\nIt\u2019s being developed in combination with other immunotherapies, where we think there\u2019s a little more of a commercial opportunity, but we still need to see more data.\u201d\n\nImlygic is approved for skin tumors that are inoperable in patients whose cancer has returned following surgery.\n\u201cBut short of that, this might be like diabetes, where we can control it and people live normal lives.\u201d\n\nImlygic is based on a form of the herpes simplex virus that commonly causes cold sores.\n\u201cIt\u2019s a low-toxicity treatment, and for the right patients you see quite stunning results,\u201d said Robert Coffin, a virologist who created Imlygic at BioVex, the Woburn-based company he founded.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug has been approved by the FDA, so we\u2019ll award a Satisfactory grade here. But the story could have gone further. Folks with advanced-stage melanoma do not have anywhere to turn; they will be keen to follow up on this information. A news release from Amgen indicated that the company would make the treatment available within a week, so more thorough availability information appears to have been, well, available.", "answer": 1}, {"article": "\"This is good news.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn the new study, Armando Giuliano of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, Calif., and colleagues analyzed data collected from 445 women who had their nodes removed and 446 who did not, along with radiation and chemotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll address the following concern under this criterion because we\u2019re not sure where else to address it.\u00a0 Readers would have benefited from early clarity that all participants in the study\u00a0still had a sentinel lymph node biopsy and that the research focused on whether removal of all lymph nodes was necessary\u00a0if the sentinel nodes were cancerous.\nThe article pointed out that if breast cancer has spread to any lymph nodes, doctors usually recommend removing all lymph nodes in the arm.\nThe article reported that\u00a0in a phone interview, Gary Lyman of the American Society of Clinical Oncology said the group may revise its recommendations for full lymph node removal based on the results of this study.\u00a0 Since many surgeons and oncologists base their advise to patients on these recommendations, patients may soon be offered this less extensive surgery option. .", "answer": 1}, {"article": "[Breast cancers predicted to rise by 50 percent by 2030]\n\nThe study released Sunday showed that the tests were about 97 percent accurate on 639 subjects.\nThe next logical question is whether those changes might be detected early enough to predict and prevent lung cancer.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\nIf the test is negative, its accuracy will allow doctors to wait and watch a lesion.\nOther research is being conducted to find markers for lung cancer, though much of it focuses on substances that can be found in the blood, Spira said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that\u00a0a company bought the test\u00a0and is \u201cmaking\u00a0it available\u201d to hospitals nationwide.", "answer": 1}, {"article": "Loading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nA recent study published in adds to the growing evidence that fiber might be a critical gut-nourishing nutrient.\nThe authors of the new study wanted to look at what changes in diet do to one particular gut microbe species: a strain that\u2019s been associated with leanness and better glucose tolerance in mice.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\n\u201cYou can eat massive amounts of plant material and it can be incredibly good for you, you can feel really satisfied and full,\u201d Sonnenburg says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions a range of healthy dietary options for increasing fiber intake \u2014 all of which are available to consumers.", "answer": 1}, {"article": "On the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\nHowever, the optimal amount of avocado and frequency of use needs further evaluation along with the nutritional similarities and differences between other different MUFA sources.\nCardiovascular disease is responsible for one out of every four deaths; it is the number 1 killer of American women and men, and it is a leading cause of disability.\n\"Through our nutrition research program, established in 2010, we are committed to increase awareness and improve understanding of the unique benefits of avocados to human health and nutrition.\nIn 2010, HAB established a nutrition research program to increase awareness and improve understanding of the unique benefits of avocados to human health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that avocados are widely available so it doesn\u2019t need to be addressed in the news release.", "answer": 2}, {"article": "Autopsies show that most men will develop prostate cancer in their lifetimes but often die of something else.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nSome doctors fear the cancer is being over-treated, particularly in older men, subjecting them to therapies that leave many impotent and incontinent when their cancer would never bother them if left untreated.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that\u00a0the study followed men who chose aggressive treatment (either surgery or radiation) or observation (also known as watchful waiting)\u00a0for early prostate cancer, indicating these options are currently available to manage early prostate cancer.\u00a0 ", "answer": 1}, {"article": "\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nIt makes sense that the probiotics may enhance the immunotherapy\u2019s effect, since probiotics are beneficial bacteria in the gut, where food allergens are processed.\nCompared to 4% of children who didn\u2019t get any treatment, 82% of those receiving the combination therapy significantly reduced their allergic reactions to peanuts.\nFewer children in the treated group had an allergic reaction to the peanuts, and they also showed smaller reactions to skin prick tests with peanut allergen.\nThe Australian team added probiotics to further enhance the gut\u2019s ability to accept the peanuts and not trigger an immune reaction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address how far along in the development process this combination therapy is, nor how far removed it may be from clinical use.", "answer": 0}, {"article": "Of these, 40% (574) were nulliparous women, 870 (60%) women completed 3 years of the study, 707 (49%) elected to enroll in an extension phase up to a total of 5 years, and 550 (38%) completed 5 years of use.\nKyleena is available by prescription only.\nKyleena is a small, flexible plastic T-shaped device containing 19.5 mg of a progestin hormone called levonorgestrel.\n\u00a9 2016 Bayer \n\nBayer and the Bayer Cross are registered trademarks of Bayer.\nThe clinical trial had no upper or lower weight or BMI limit.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that Kyleena will be available by prescription in October 2016.", "answer": 1}, {"article": "The American Academy of Pediatrics currently recommends 400 units a day for infants.\n\"It was believed that megadoses of vitamin E, beta-carotene, selenium, folic acid and the B vitamins would confer a large array of health benefits.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\n\"There's overwhelming evidence ... that increasing your vitamin D intake can make substantial improvement in your overall health and welfare,\" says Dr. Michael Holick of Boston University.\nDr. Cliff Rosen of Portland, Maine, knows a lot about vitamin D. It's necessary for strong bones, and Rosen is a leading bone specialist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story did mention various means to increase one\u2019s level of vitamin D including supplements, fortified foods, and exposure to sunlight. \u00a0It would have been useful to mention that vitamin D is commonly found in multivitamins, and many calcium supplements contain vitamin D as well. ", "answer": 1}, {"article": "Macular degeneration patients often are advised to take certain vitamin combinations that may help stave off advanced disease.\nWhile there\u2019s no treatment for the advanced dry form, the \u201cwet\u201d form occurs when leaky blood vessels grow under the retina \u2014 and there are several therapies that can help those patients preserve vision.\nThose are the only patients who appeared to benefit from the drug; they had 44 per cent less eye damage than the untreated patients, the Genentech team reported Wednesday in the journal Science Translational Medicine.\nThe hypothesis: Genentech\u2019s drug, lampalizumab, essentially offers a backup method for tamping down the immune reaction.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that the drug is not yet available, when it explains that the drug company plans to \u201copen two large-scale studies that aim to prove if the drug works. Results are expected later this year.\u201d", "answer": 1}, {"article": "I was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI volunteered, to get myself out and doing things, to fill the gaps,\u201d she said.\nAfter he died in 2002, she sold the Long Island house they\u2019d loved and shared, finding it too filled with memories, and moved to their country home in upstate New York.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cThe pain just didn\u2019t go away,\u201d she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A consumer cannot tell from this story whether complicated grief therapy is widely available outside of research centers in urban areas.", "answer": 0}, {"article": "\"For patients, the concept that psoriasis is 'just something you live with' is no longer appropriate,\" he said.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nAn ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the study was a phase II clinical trial, and that a phase III trial is ongoing. In other words, the drug will not be available in the very near future. Ideally, the release would remind journalists \u2013 and the public \u2013 what a Phase II trial means and what it doesn\u2019t mean.", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nResearchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The journalist probably assumed that yoga and stretching programs are widely available in the U.S.\u2014which is a reasonable assumption. So the article wins a \u201csatisfatory\u201d on this point.\nBut in fact, it is not all that clear that similarly standardized \u201cviniyoga\u201d classes designed to accommodate back pain patients are widely available\u2014or whether most health insurance plans will cover them.\u00a0 Intensive stretching classes would appear to be uncommon. So physical therapists or exercise physiologists might have to create them based on the study model.\n\n\n\n ", "answer": 1}, {"article": "Moffitt is the No.\nThe researchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\n\"The observed benefit of neoadjuvant radiation therapy aligns with the growing body of literature of the immune activation effects of radiation, including shrinking of untreated metastases outside the radiation field,\" explained Heiko Enderling, Ph.D., associate member of Moffitt's Integrated Mathematical Oncology Department.\nThese findings are worthy of a prospective clinical trial to confirm potential benefits of neoadjuvant vs. adjuvant radiation, and to identify the potential contribution of radiation-induced immunity to vaccinate against future disease,\" said Enderling.\nTheir study, published in the June 30 issue of Breast Cancer Research, found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The evidence comes from the SEER database which has been collecting data on cancer incidence for several decades, indicating that the treatment has been performed. However, the authors clearly state a need for further clinical trials to validate their hypotheses that pre-surgical radiation is a good option.", "answer": 1}, {"article": "And we were thrilled to see such a huge impact.\nIt shows that palliative care and cancer care aren\u2019t mutually exclusive.\u201d\n\nDr. Atul Gawande, a Harvard Medical School surgeon and writer who just published a long article in The New Yorker about hospitalized patients\u2019 suffering before death, called the study \u201camazing.\u201d\n\n\u201cThe field was crying out for a randomized trial,\u201d he added.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\nSaying the study was \u201cof critical importance,\u201d Dr. R. Sean Morrison, president of the American Academy of Hospice and Palliative Medicine, said it was the \u201cfirst concrete evidence of what a lot of us have seen in our practices \u2014 when you control pain and other symptoms, people not only feel better, they live longer.\u201d\n\nThere is sometimes tension between medical specialties, since surgeons and oncologists often view cancer as a battle, while palliative care specialists are seen as \u201cgiving up.\u201d\n\nPalliative care typically begins with a long conversation about what the patient with a terminal diagnosis wants out of his remaining life.\n\u201cThe billing is complicated, and for many physicians that\u2019s enough of a deterrent to not bother.\u201d\n\nDr. Cooney herself had such care along with surgery and chemotherapy for ovarian cancer in 2008.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mixed bag here. The Times noted that Medicare pays for some palliative care services but that billing difficulties may deter physicians from offering\u00a0it.\u00a0However, there was no mention of the difficulty patients may have accessing\u00a0the type of outpatient palliative care services that were offered in this study. Most non-hospice palliative care is currently provided only in the inpatient / acute care hospital setting. A borderline\u00a0satisfactory.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The higher cost of IUDs and implants can be a significant barrier to availability, as can access to health care providers trained to insert these devices. The story briefly mentions cost issues and lack of insurance coverage for these two options, but it is not clear how often lack of access to care affects availability.\u00a0 We\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "She said self-exams may not reveal tumors early enough to improve survival.\n\"One danger of pushing breast self-exams on patients is that they may be falsely reassured by it and opt out of their mammograms,\" said Dr. Heidi Nelson, medical director of the\n\nin Portland.\nThe preferred method, known as the vertical strip, three-pressure test, has proved the most sensitive and least likely to produce false alarms, Steiner said.\nDuring the women's health movement of the 1970s, the self-exam gained importance as a means for women to take charge and rely less on a paternalistic health system.\nSelf-exams also appeal strongly to some younger women, whose main screening test is a manual exam done by a doctor or nurse.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of breast self-exams (BSE) is implicit; however, the story appropriately notes that not all physicians or health educators know current BSE technique, and there is a suggestion that inappropriate technique may influence the sensitivity of the self-exam. The story mentions a more sensitive technique\u2013the vertical-strip, three pressure test\u2013 used in Canada, which has been validated in a small subset of women. ", "answer": 1}, {"article": "About 15 percent of dialysis patients have HCV, the researchers said.\nTUESDAY, Aug. 7, 2018 (HealthDay News) -- Dialysis patients waiting for kidney transplants might safely accept an organ from a donor infected with hepatitis C virus (HCV), a new study finds.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\n\"Because of the opioid crisis, there are many people who die from a drug overdose and have HCV and want to donate their organs.\"\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job of explaining what steps would need to be taken to make kidneys and other organs from infected donors available. Who would have to approve of this protocol? And what further evidence is required to confirm that it\u2019s safe?\nMoreover, it\u2019s not clear how much the wait would be shortened by making HCV-infected kidneys available to patients who don\u2019t have the virus. According to data cited in an accompanying editorial, 3,562 kidneys from donors with HCV have been discarded in the U.S. since 1995; that number seems small compared to the number of people in need of a kidney.\nAlso, given a rise in HCV-infected kidneys from young donors due to the opioid crisis, it seems that efforts to curb opioid misuse might diminish the availability of those organs.", "answer": 0}, {"article": "Stryker says that none of the problems underlying the recall or the warning letter from the F.D.A.\n\u201cPublished research shows squeaking is rare compared with other total-hip-related risks like infection, dislocation and leaving patients with uneven leg length.\u201d\n\nBut plaintiffs lawyers, who have already filed scores of lawsuits on behalf of ceramic hip patients, are gearing up to argue that squeaking is not a minor problem for many who experience it.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\n\u201cThere is no evidence that the wear associated with squeaking would lead systems to fail,\u201d said Dr. James A. D\u2019Antonio, an orthopedic surgeon outside Pittsburgh, who was a chief investigator on the clinical trials that led to regulatory approval for Stryker\u2019s Trident.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly state that ceramic hip replacements are approved by the FDA, but with \u201ctens of thousands\u201d implanted, it\u2019s clear that surgeons\u2019 adoption of the devices is widespread. The FDA\u2019s warning to implant maker Stryker about squeaking suggests the devices may not be perfect, but are approved.", "answer": 1}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nSimilarly, weight loss reduced stress and depression.\nDuring this part of the trial, the participants lost an average of almost 14 pounds.\nThis study encourages weight loss in a more holistic context,\" he said.\nThose in the second phase of the trial continued their diet and exercise program.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.", "answer": 2}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The strategy of direct referral to invasive coronary angiography without noninvasive imaging is obsolete,\" Dr. Kaufmann said.\n\"In patients with multiple lesions or complex coronary anatomy, it is, in many cases, very difficult to correctly identify the culprit lesion,\" he said.\nIf a lesion was evident, then clinicians could employ a nuclear scan to assess ischemia and take advantage of both modalities by fusing the results together to make a hybrid image.\nInvasive coronary angiography (ICA) is considered the gold standard for determining the percent of stenosis, or narrowing, due to plaque in a coronary artery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how widely available the hybrid approach is. Given that the hybrid approach is really just a combination of two existing tests (a CT scan and a nuclear scan) it stands to reason that it should be available in most medical centers but the release fails to explain this.", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nIf a parent is also found to have the abnormality, geneticists conclude that the couple is at higher risk of having a child with autism.\nBut if the parents don't have the abnormality, geneticists conclude that the deletion or duplication happened by chance, and the parents are probably not at any greater risk of having another child with autism than the general population, Marion said.\nThe study appeared online March 15 and will be published in the April print issue of Pediatrics.\nWhile both Children's Hospital Boston and Montefiore have offered CMA testing for several years, not all hospitals do, nor does all insurance pay for it, the researchers noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that not all hospitals offer the newer chromosomal microarray analysis (CMA) test. It could have also mentioned that genetic counseling services are not widely available in some geographic areas. ", "answer": 1}, {"article": "But the triggers are different for different people.\n\"The majority of them have really been suffering a number of years and they're really miserable with the pain,\" Bernstein says.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\n\"If you are a migraine sufferer and I expose you to the right trigger, you're going to have a migraine,\" Bernstein says.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "If the concept is that lifestyle changes are effective at treating migraines, then it is assumed that people can change their diets or exercise more no matter where they live. The story supports that impression, and we\u2019ll award a satisfactory on that basis. For extra credit, the story could have elaborated on why it was so hard for the woman in this story to find a doctor to prescribe this kind of therapy. Are doctors who embrace this approach difficult to locate? If these approaches are effective, why aren\u2019t they more widely used?", "answer": 1}, {"article": "Now we can get a diagnosis sooner.\"\nThe DaTscan injection was first used in Europe a decade ago, and GE Healthcare made it available to U.S. hospitals in late June.\n\"I was thrilled there was something that could positively tell me I had Parkinson's because everybody had guessed what I had,\" said Ray Ramas, 56, who in June became the first patient at Central DuPage to undergo the scan.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nIt is the first \"radiopharmaceutical adjunct imaging agent\" approved by the Food and Drug Administration that helps physicians better evaluate patients who are thought to have Parkinson's disease or other parkinsonian syndromes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe availability of the DaTscan test is the main point of the story. It reports the test was approved by the FDA in January 2011 and is now available at more than 80 hospitals in the United States. It also reports that the test was approved for use in Europe a decade ago. ", "answer": 1}, {"article": "\u201cCounting is expensive.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\n\u201cThis is just a theory that can explain our results, so it needs further testing.\u201d\n\nAnother explanation is that merely injecting any substance into a knee offered relief from pain.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nThe findings in The American Journal of Sports Medicine include an anomalous finding \u2014 patients not only had a dramatic improvement in the knee that received stem cells, but also in their other knee, which also had painful arthritis but received only a saline control injection.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release prominently notes the wide availability of regenerative medicine clinics and their offerings of BMAC for knees and other arthritic joints. And it makes clear that the results of this new small trial cannot underpin recommendations for its \u201croutine\u201d use. The release would have been stronger if it had explained what \u201cnon routine\u201d use means in the context of the study\u2019s findings.", "answer": 1}, {"article": "There is also another issue.\n\"Part of it is that this area of medicine we're practicing in is kind of a high wire act,\" said Dr. Michael Lee, an oncologist in private practice in Norfolk, Va. \"It is more comfortable to adopt things that are aggressive.\"\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\nThe chemotherapy question starts with American and European guidelines that say almost every woman with breast cancer that has gone beyond its earliest stages, when it is confined to the milk duct, should have the treatment.\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that adjuvant chemotherapy is widely used in breast cancer treatment. Established clinical guidelines based on current evidence suggest that most women with invasive breast cancer and lymph node involvement should not forgo chemotherapy. Physicians are cautious about changes in practice at this time, but some are already presenting the new data to patients and suggesting that chemotherapy may be tailored to a patient\u2019s type of breast cancer. ", "answer": 1}, {"article": "The F.D.A.\nTimothy Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, said in a recent note that Entresto was \u201clikely to become a mega-brand over time\u201d but that the initial uptake was \u201clikely to be on the slower side given the entrenched nature of off-patent ACE inhibitors.\u201d He said it was highly unusual that there were no major competitors for Entresto on the way, giving it a \u201clong runway.\u201d\n\nIn a clinical trial with more than 8,400 participants, patients were randomly assigned to take either Entresto or enalapril, an ACE inhibitor.\nThe other ingredient, sacubitril, inhibits an enzyme known as neprilysin, a new mechanism of action for a heart failure drug.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nAfter about 27 months, 21.8 percent of those taking Entresto had either died from cardiovascular causes or had been hospitalized for worsening heart failure, compared with 26.5 percent for those taking enalapril.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about the FDA approval of the drug, which suggests that it will shortly be available for purchase. Novartis says as much in its news release which indicates the drug will begin shipping this week. The story doesn\u2019t explicitly address this, but we\u2019ll give the benefit of the doubt. Again, we\u2019d add that half of this drug combination is already widely available.", "answer": 1}, {"article": "\"Whether the vaccine is going to look anything like this one I don't know.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\n\"Conceptually, we now know a vaccine is possible,\" said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, which paid for most of the six-year trial.\nThe vaccine, a complicated mixture of six \"prime\" and \"booster\" shots, reduced a person's risk of becoming infected by about one-third compared with people getting placebo injections.\n\"We really need to go through the data to see if there are effects here that are potentially useful,\" said Col. Jerome Kim, a physician involved in the study, which was run by the U.S. Army, the National Institutes of Health and Thailand's Ministry of Public Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental stage of the vaccine research is clear from the story, as when it states: \nThe vaccine is not licensed or being produced in large amounts. It is unlikely \u2014 but not impossible \u2014 that any country would consider it effective enough to be used as a public health measure against HIV. ", "answer": 1}, {"article": "\"Sure.\nBut we were surprised by how healthy he seemed seven months later, in August 2008, when we visited with him and his wife Marianne at their home in Erie, Pa.\n\n\"I must say you look like a completely different person to me.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\n60 Minutes decided to keep track of Kanzius and his invention, so we followed him for over a year, as he pushed to speed up the research on his machine and fought to slow down his own cancer, which was killing him.\nUsing his wife's pie pans and what he knew best - radios - Kanzius, a former radio executive, built a machine in his garage that he hoped would zap cancer cells without the horrible side effects you get with chemotherapy and radiation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story quotes one of the developers of the device as saying that the start of human clinical trials could begin within two to four years. Viewers are not given a clear explanation of the rudimentary stage of the investigation of this device.\n Viewers would also likely be confused about the distinction between initiating clinical trials and actually bringing a product to market. When the researcher says they would \u201csucceed,\u201d he is apparently referring to initiating trials; but it is likely that many viewers believed he was predicting that ultimately the treatment would be successful.", "answer": 0}, {"article": "To automatically receive news releases from UT Southwestern via email, subscribe at http://www.\nIn contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,\" said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\nIt is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.\nThe Harold C. Simmons Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in North Texas and one of just 45 NCI-designated Comprehensive Cancer Centers in the nation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release hints that SBRT is available at the study location but does not provide readers with any other indication about its availability in other regions. We do know that SBRT is widely available at other academic medical centers and has been in use for more than a decade. It is also sometimes marketed as the \u201cCyberKnife\u201d at private medical facilities.", "answer": 0}, {"article": "Of the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime, almost a third remain undiagnosed due to a lack of reliable tests available to gastroenterologists.\nSuch an immune mechanism has never been reported before.\nThe trials were conducted with colleagues from Monash University.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\nMelbourne based start-up Atmo Biosciences is set to commercialise this revolutionary technology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s implied the capsule is in development and not commercially available at this time.", "answer": 1}, {"article": "(Reuters Health) - Taking one or two baby aspirins a day for at least five years was tied to a lower risk of colorectal cancer in a study from Denmark.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\n\u201cUnless low-dose aspirin is taken continuously, there is little protection against colorectal cancer,\u201d Dr. Soren Friis from the Danish Cancer Society Research Center in Copenhagen told Reuters Health.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\n\u201cLow dose aspirin, already taken regularly by millions, reduces the risk of colorectal cancer,\u201d he told Reuters Health by email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ubiquity of low-dose aspirin is so well known that it did not need to be mentioned.", "answer": 1}, {"article": "\"For all practical purposes, the programs all worked about the same,\" said Kelly D. Brownell, director of Yale University's Rudd Center for Food Policy and Obesity and creator of the Lifestyle, Exercise, Attitudes, Relationships and Nutrition (LEARN) program for weight management, one of the diets studied.\nThe findings confirm, he said, that reducing carbohydrates, \"especially those with refined starch and sugar like that found in the U.S. diet, has metabolic benefits.\"\nAs for weight loss, the goal that concerns dieters the most, none of the groups managed to shed the large numbers of pounds touted by weight-loss programs and television shows such as \"The Biggest Loser.\"\nThe study by Stanford University researchers compared the Atkins approach with three others: the standard low-fat, reduced-calorie regimen long recommended by many physicians and weight-loss experts; the Zone, a reduced-carbohydrate approach developed by author Barry Sears; and the very low-fat, high-carbohydrate regimen created by Dean Ornish.\nA year-long, head-to-head study of four widely used diets found that overweight women who followed the very low-carbohydrate Atkins diet had no adverse health effects and lost slightly more weight than women on the other three.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a study that compared weight loss of overweight and obese individuals who followed one of four popular weight loss diets.\u00a0 The story mentioned that the people in the study were given a book on the diet that they were assigned to follow and\u00a0the books used are available commerically.\u00a0 It would have been helpful to readers to include explicit details on the specific books used.", "answer": 1}, {"article": "But many others are tough calls.\n\"A biopsy takes a few minutes in my hands, so if there's an issue with any lesion we will always biopsy, whether we have a MelaFind picture or not,\" said Dr. Leonard Goldberg, a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\n\"The device is only good for certain lesions, and that's why you have to be a dermatologist to be able to classify and categorize those lesions appropriately,\" said Christy Foreman, director of FDA's Office of Device Evaluation.\nThe Food and Drug Administration on Wednesday approved a first-of-its-kind device, called MelaFind, that makes detailed, digital images of skin growths and uses a computer to analyze them for signs of cancer, offering a sort of second opinion to doctors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says clearly that the devices are not currently available in most areas. \u201cBut don\u2019t expect to see a MelaFind machine at your next doctor\u2019s appointment. The company plans a limited rollout next year of just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\u201d", "answer": 1}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nMany researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nIn May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that statin medications are a popular medication for managing cholesterol levels and so it was clear that they are currently in use.\nIt would have been useful to indicate that these are prescription medications available in both brand name and generic versions.", "answer": 1}, {"article": "So why does acupuncture seem to work?\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\n\"Anyone who treats breast cancer struggles with this problem in their practice, because the hot flashes that some women experience with anti-hormonal treatment can be profound,\" she said.\n\"And I've actually had patients who have had acupuncture with good success, so I'm not surprised by the finding,\" she added.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One can infer from the story that acupuncture treatment is available for breast cancer patients, particularly given that the independent source says her patients have used acupuncture in the past. And because most people are generally aware that acupuncture is available, we\u2019re giving this a Satisfactory rating.\nBut, the story would have been stronger if it had told readers whether any certified acupuncturist can provide the relevant therapy, or if a specialist in hot flashes is necessary.", "answer": 1}, {"article": "In fiscal year 2014, Penn Medicine provided $771 million to benefit our community.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\nThey work by promoting the release of dopamine, which is impaired in ADHD and other disorders characterized by executive function problems.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release establishes that the drug used in the study is now frequently prescribed for ADHD patients, suggesting that it is available and also could also be used for menopause-related symptoms..", "answer": 1}, {"article": "Crohn\u2019s is a chronic autoimmune disorder of the gastrointestinal tract that affects an estimated 700,000 Americans.\n\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\n\u201cTo see these kind of outcomes, where you have high response rates in the short term and then good remission rates out toward five or six months of therapy, it shows unequivocally that the drug is effective for treating Crohn\u2019s disease,\u201d said Dr. William Sandborn, the study\u2019s lead investigator, who presented the data at the Digestive Disease Week meeting in Chicago on Sunday.\nIn addition, nearly 70 percent of patients who stayed on Stelara beyond the initial six weeks of the mid-stage study continued to respond to the drug and there was a significantly higher rate of remission at 22 weeks than in a placebo group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was borderline on this criterion. On the plus, the current indication is mentioned, as well as trials into other conditions. But on the minus,\u00a0our standard requires that articles provide readers with information about what phase of research the drug is in. It\u2019s not clear what phase the study is at and how close the drug is to the market in even the best-case scenario.\nThe article calls the trial \u201cmid-stage.\u201d According to the press release, that means phase 2b. Many readers won\u2019t know the significance of mid-stage, or that it\u2019s only at the \u201clate-stage\u201d (phase 3) that trials are designed to meet FDA requirements.\u00a0If it\u2019s phase 2b, mid-stage, generally we\u2019d expect another 2-4 years before piggy gets to market.\u00a0That\u2019s why we like to see a statement about exactly when patients could expect to see this medicine available to them. (Off-label use could occur before FDA approval, but given the expected price, it\u2019s unlikely to be covered off-label.) It tempers the hope of a breakthrough with the reality that, even if it aces its upcoming exams, the drug probably won\u2019t be readily available to patients until 2013-2015.", "answer": 0}, {"article": "The devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nHeart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nBut they are most often used in patients who have a blocked artery and chest pain that occurs, for example, walking up a hill or going up stairs.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Stenting procedures are clearly widely available in the U.S. and across the world. What\u2019s less clear, the story says, is whether guidelines or practice for stenting will change in the U.S.: \u201cThe idea that stenting relieves chest pain is so ingrained that some experts said they expect most doctors will continue with stenting, reasoning that the new research is just one study.\u201d We thought this was an interesting point and are glad it was included.", "answer": 1}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nThe hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\n\"For the eating-in scenario, overnight closed loop delivery increased the time plasma glucose levels were in target by a median 15 percent,\" said Hovorka.\nPrevious research suggests that in a 24-hour period, the average person with type 1 diabetes spends about 10 hours with blood sugar levels too high, and about an hour a day with blood sugar levels too low, according to Aaron Kowalski, assistant vice president for treatment therapies at the Juvenile Diabetes Research Foundation.\nAn analysis of pooled data showed that the overall time that plasma glucose levels were in target \"increased by a median 28 percent\" with the artificial pancreas, said the study's lead author Roman Hovorka, a principal research associate at the University of Cambridge in the United Kingdom.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are such a widely prescribed class of drug that we feel most readers will understand their availability. The story does hint at this by noting that one-third of the patients who had surgery in this study were taking statins.", "answer": 1}, {"article": "In a new paper published on May 31 in the journal PLOS One, researchers from Duke believe they have found a better way.\nWhile more than 4,000 American women die of the disease each year, the mortality rate has dropped more than 50 percent in the past four decades, largely due to the advent of well-organized screening and diagnostic programs.\n\"The mortality rate of cervical cancer should absolutely be zero percent because we have all the tools to see and treat it,\" said Nimmi Ramanujam, the Robert W. Carr, Jr., Professor of Biomedical Engineering at Duke.\nThe colposcope is a magnified telescopic device and camera designed to allow medical professionals to look through the speculum to see the cervix, which is located three to six inches inside the vagina.\n\"We recruited 15 volunteers on Duke's campus to try out the new integrated speculum-colposcope design,\" said Mercy Asiedu, a graduate student working on the project in Ramanujam's lab.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not clearly state that the device is currently unavailable. Savvy readers may glean this from the description, but a more direct statement and discussion of the steps involved before the device can be commercially produced and used would have been helpful.", "answer": 0}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\n\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Lidocaine creams come in many different over-the-counter products but it\u2019s unclear whether the lidocaine formulation used in the study is the same as one might find over-the-counter, or if it\u2019s EMLA (a cream using equal parts lidocaine and prilocaine) or another prescription product.", "answer": 2}, {"article": "Moreover, though resting energy expenditure varies with each individual, this increase would yield almost 1 lb.\n\"Since Capsimax is made using a proprietary beadleting technology, OmniBead, which coats the capsicum extract, releasing it only when it reaches the intestines where it is absorbed without discomfort, we were able to deliver beneficial levels of capsaicinoids to our subjects, which made the MR Study possible.\"\n\"Because capsaicinoids (the component of hot peppers that gives them heat) are hot, it was imperative that we use an ingredient which the subjects could tolerate,\" said Vijaya Juturu, Ph.D., F.A.C.N., one of the lead researchers on the MR Study.\nNow, with the publication of the MR Study, there is yet another demonstrated benefit of Capsimax as a natural, stimulant-free approach to weight management, sports nutrition and a healthy lifestyle as we age.\"\nA recent paper, Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device-An Open Label Placebo Controlled Acute Study, published in the journal Obesity Open Access discussed the findings of the Metabolic Rate (MR) Study, which demonstrated that an extract from red hot peppers boosted metabolic rate (Chen, et al., 2017).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t offer any advice to readers about where to acquire Capsimax \u2014 just that it\u2019s available in \u201chundreds\u201d of products. An online search for \u201cCapsimax\u201d turns up numerous products containing the extract but\u00a0 can people shopping for supplements online be assured of purity of ingredients and accuracy of dosing? The release could have done a lot better job by directly people to reputable sources of the supplement.", "answer": 0}, {"article": "THURSDAY, May 3, 2018 (HealthDay News) -- Much of the debate over when to start having mammograms has focused on lives saved, but new research suggests that early screening might also translate into smaller tumors and less aggressive breast cancer treatments.\nStill, \"the observations are consistent with what we have seen with the value of early detection.\nAlso, because of the nature of the study and the small sample size in the young age group sub-analysis, Lichtenfeld said that \"this cannot be interpreted as a study telling us what age to start mammograms.\"\nClearly, the earlier a breast cancer is diagnosed, the less treatment that will be required.\nFindings presented at meetings are typically viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We believe that mammograms are well-known to be widely available. And the earlier and more frequent screening described here is not earlier or more frequent than what many guidelines recommend, so would not be expected to be denied by health insurers.", "answer": 1}, {"article": "The other groups showed no significant change.\nEating fewer calories may lead to better memory, a new study says.\nThen they took tests involving memorizing words.\nA third group made no dietary changes.\nMembers of a second group kept their calories the same but were instructed to increase the unsaturated fat (healthy fat) they ate by 20 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of caloric restriction is not in question.", "answer": 2}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the company that makes the Oncotype DX test, Genomic Health, plans to start selling the test early next year. \nBut the reader has no idea how realistic this prediction is. Given the economic self-interest of the source, the story should have indicated what regulatory or commercial barriers the company faces before it can bring the test to market.\u00a0 ", "answer": 0}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges that the results are preliminary and the test is [in the best-case scenario] a few years away from being clinically available. The investigator\u2019s quote that \"It might take three or four more years before these tests are clinically available\" assumes the test will be proven valuable in trials, which is a premature claim. Availability is not inevitable.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the vaccination is already in use for people over age 65.\u00a0 ", "answer": 1}, {"article": "In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.\nIn such cases the drug is temporarily discontinued and reintroduced at a lower dose.\nThe lower their neutrophil count, the more vulnerable patients are to infectious diseases.\nAlthough, median progression-free survival was four months, five patients had progression-free survival greater than one year.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether this drug is currently approved or how widely this drug is used.", "answer": 0}, {"article": "Utilizing IceCure Medical's innovative IceSense3\u2122 cryoablation system, the multi-center trial is examining cryoablation of certain types of breast cancer.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\nWe are excited to be participating in this trial where some breast cancer patients can be treated without surgery,\" adds Richard Fine, MD, The West Comprehensive Breast Center, Memphis, TN, another surgeon active in the cryoablation trial.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\nAs a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to sites in the cancer trial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told ICE3 is currently in clinical trials for treating breast cancer and is only available at 20 US sites, at least two of which are named in the release.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that boceprevir is an experimental drug currently in development. ", "answer": 1}, {"article": "Adding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\nThis appeared to be due to reduced appetite and food intake.\nThey can see that their unexpected and unpredictable oscillations of blood sugar are minimized.\nJune 7, 2011 - People with well-controlled type 1 diabetes had even better sugar control, used less insulin, and lost an average of 10 pounds in six months when taking the type 2 diabetes drug Victoza in a small clinical study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the drug is not approved for use in type 1 diabetes, but that it could be used off-label in this population by a diabetologist since it is approved for use in type 2 diabetes.", "answer": 1}, {"article": "\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\n\"We had amazing responses,\" Reich says.\n\"We in dermatology have never spoken about remission before.\nThose same results were achieved by about 10% to 20% of 163 patients in the methotrexate group.\n\"This is unheard of,\" Reich tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of briakinumab was made clear in the story.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nIt costs $179 to pre-order a tester plus three one-time-use pods, and $47.95 for a refill pack of 12 pods; prices will increase later this month, according to the company's website.\n\"One of the things that we wanted to make sure we distinguish is that we don't see ourselves as a medical device,\" Sundvor told CBS News.\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nSo we started talking about the idea and we researched the market and realized it's something we could make happen.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the product is a bit vague, but it\u2019s there.\u00a0The timeline of \u201cthe middle of next year\u201d is provided for availability.", "answer": 1}, {"article": "Scores more than three times the average person's risk were deemed high.\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\nOther scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\n\"There are things you can do to lower the risk,\" Kathiresan said \u2014 the usual advice about diet, exercise, cholesterol medication and not smoking helps.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One of the researchers suggests that \u201cin five years, each person will know this risk number, this \u2018polygenic risk score,\u2019 similar to the way each person knows his or her cholesterol,\u201d making clear that the technology isn\u2019t available to patients now.\u00a0 Moreover, the story adds that he \u201chopes to open a website where people can send in such data to learn their heart risk,\u201d something that clearly doesn\u2019t exist yet.", "answer": 1}, {"article": "The bad news is that there is no benefit of being less likely to develop heart disease, and any reduction in the risk of hip bone fractures evaporates with time, according to a report in the latest issue of the Journal of the American Medical Association.\nHormone use plummetted, but women who had been using the drugs were left to wonder whether they were still at risk.\nThe women had taken estrogen for about six years.\nAt the same time, the women continued to be at a lower risk for breast cancer.\nThe researchers found that the risk for heart disease during the follow-up period was similar to that seen while the women were taking the hormone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nEstrogen is widely available, so the story does not need to dwell on this.", "answer": 2}, {"article": "After six months, they showed less DNA damage, healthier sperm shape and lower levels of metabolic stress factors.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center.\nIn the study, Behzad Maleki at Justus-Liebig University in Germany and his colleagues recruited 280 sedentary, middle-aged men and randomly assigned them to one of three exercise regimens, or to no exercise, and followed them for six months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Exercise \u2014 in this case, running \u2014 is clearly a readily available activity for most individuals.\u00a0 They simply have to decide to do it. Some explanation of the availability of effective HIIT training could have been added, though.", "answer": 2}, {"article": "For more information about NIH and its programs, visit http://www.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the drug is not clear in the release. Although this is a previously approved drug that can be prescribed by doctors, some insurers may not cover it or cover it with higher co-payments. This could have been mentioned in the release. ", "answer": 0}, {"article": "For more information, visit http://www.\nAfter six months of treatment, more than 93 percent of 901 respondents reported their pain dropped from a median of eight to four on a 10-point scale.\nClose to 60 percent of patients who originally reported \"bad\" or \"very bad\" quality of life upgraded to \"good\" or \"very good\" after six months.\nRecent U.S. polls indicate Americans over 65 represent 14 percent of the total population and use more than 30 percent of all prescription drugs, including highly addictive painkillers.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not address which countries (other than Israel) or US states have legalized medical marijuana. Availability depends very much on where the patient lives.", "answer": 0}, {"article": "TUESDAY, June 14, 2011 (HealthDay News) -- Not only do cooler heads prevail, they might also sleep better, according to researchers who say they have developed a cooling cap that, when worn during sleeptime, may help treat insomnia.\nThe U.S. National Heart, Lung, and Blood Institute has more on insomnia.\n\"It does reduce brain metabolism in the frontal lobes, and it improves sleep.\"\nMedications can help, although many people complain of side effects, Kohler said.\nBuysee said there shouldn't be any safety issues.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the approach is experimental and not yet available to consumers.", "answer": 1}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThey found that patients 10 years and older saw no benefit from decadron, and, in fact, were at much higher risk for a debilitating bone condition called osteonecrosis.\nThe investigators found that patients in either arm responded very well overall to treatments, but those in the high dose group had a significantly better outcome, by 5 to 6 percent, which translated into a significantly decreased relapse rate for these patients.\nDuring this clinical trial, the investigators decreased the duration of decadron from 28 days to 14 to determine if patients could avoid the side effect of increased infection while still benefiting from the steroid's anti-leukemic effects.\nPrevious studies by the Children's Oncology Group showed that in standard risk ALL patients--those with low white blood cell counts or under 10 years of age--decadron prevented relapse in both the spinal fluid and in the bone marrow.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use.", "answer": 1}, {"article": ".\nThe nonsurgical approach uses a hysteroscope -- a camera-tipped instrument -- to thread two small wires through the vagina, cervix and uterus and into the fallopian tubes.\nThe procedure is very effective (there is less than a 1 percent chance the man's partner will get pregnant) and takes about 10 minutes to perform in the doctor's office.\nThe wires, composed of polyester fibers and metals, cause inflammation and, over time, scar tissue that blocks the fallopian tubes, preventing sperm from reaching eggs.\nIn the increasingly popular \"no-scalpel vasectomy,\" a doctor uses an instrument called a dissecting forceps to poke a very small hole in the skin of the testicles to reach the vas deferens.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the Essure approach was relatively recently approved (in 2002), it does not comment on how widely it is available, how many providers have the special training required\u00a0and whether access may be limited as a result. ", "answer": 0}, {"article": "\"The pulses correlate with the stomach's motions, enhancing a natural response to help control food intake,\" says Xudong Wang, a UW-Madison professor of materials science and engineering.\nIn fact, Wang's device contains no batteries, no electronics, and no complicated wiring.\nIt relies instead on the undulations of the stomach walls to power its internal generators.\n\"It's automatically responsive to our body function, producing stimulation when needed,\" says Wang.\nThat gentle stimulation dupes the brain into thinking that the stomach is full after only a few nibbles of food.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the device is experimental, and that further animal and human testing lie ahead.", "answer": 1}, {"article": "A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\n\"This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\"\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release squeaks through here, describing nivolumab as \u201cone of the drugs represented among the growing arsenal of immnotherapy therapies.\u201d This might imply to the reader that the drug is already available to treat other conditions. However, it does not state specifically whether the drug has FDA approval for anal cancer or any other application.", "answer": 1}, {"article": "Bochner teamed up with Northwestern oncologist Dr. Leo Gordon and colleagues to test if this BTK inhibitor could shut down an enzyme inside cells that is involved when you have an allergic reaction.\nThe cancer patients who were allergic to allergens such as cat dander and ragweed saw their allergic skin test reactivity reduced by 80 to 90 percent in one week, and this persisted with continued use of the drug for at least one to two months.\n\"Maybe they'll increase from being able to eat just one peanut to 10 before they react.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nCHICAGO --- A cancer drug for patients with certain types of leukemia and lymphoma can also prevent reactions to some of the most common airborne allergies, according to a recent Northwestern Medicine study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is clear that the drug is still being studied. It does not make any claims about when such treatments might be available.", "answer": 1}, {"article": "Researchers report these findings in the journal Archives of General Psychiatry.\nDown the road, the \"fantasy\" is that asymptomatic people will be able to get a biomarker test to determine whether they'll one day get Alzheimer's, but that's not possible right now, he adds.\nThe research builds on a 2006 Lancet Neurology study that followed patients for a median of 5.2 years, beginning with a group of 137 volunteers with mild cognitive impairment.The new study is important because of the long follow-up period, according to Adam Brickman, assistant professor of neuropsychology at Columbia University School of Medicine, who was not involved in the research.\nThe results from the study suggest that beta-amyloid is a much earlier predictor of Alzheimer's disease than tau, which supports the hypothesis that beta-amyloid accumulation in the brain occurs first in the course of the disease.\nAs scientists gain more insight into predicting Alzheimer's, aging adults may struggle with the question of whether they want to know their risk, especially since there's still no cure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, the independent expert\u2019s perspective was important:\n\u201cWhen these sorts of studies get published, Brickman and other doctors get phone calls from aging adults wondering whether they should be getting spinal taps to assess their risk.\u00a0 But it\u2019s too early to use this as a diagnostic tool in clinical settings, says Brickman. Down the road, the \u201cfantasy\u201d is that asymptomatic people will be able to get a biomarker test to determine whether they\u2019ll one day get Alzheimer\u2019s, but that\u2019s not possible right now, he adds.\u201d", "answer": 1}, {"article": "For more nutrition information and to access a vast collection of healthy potato recipes, please visit http://www.\nIn fact, a study of elementary school students demonstrated that students are not consuming the majority of vegetables offered to them in school lunches.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\nNutrient Density and the Cost of Vegetables from Elementary School Lunches.\nToday, as the largest vegetable commodity board, the USPB is proud to be recognized as an innovator in the produce industry and dedicated to positioning potatoes as a nutrition powerhouse--truly, goodness unearthed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s obvious that potatoes are widely available.", "answer": 2}, {"article": "The results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\nThe condition tends to develop with age and can lead to chest pain, shortness of breath, fatigue and heart failure.\nOverall, the current analysis included 2,775 patients from a total of 20 previously published studies on outcomes for this type of surgery.\nAfterward, patients could walk significantly further in six-minute walking tests used to assess their functional capacity.\nOn average, they added almost 42 meters (138 feet) to their performance before surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss how widely available these procedure are.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Tens of thousands of kids may benefit from cholesterol-lowering medication, but no one would know because screening guidelines exclude too many children, U.S. doctors said Monday.\nHeart disease is the leading cause of death in the Western world.\n\u201cI have gradually become convinced that universal screening in children is not only preferable, but necessary,\u201d said Neal.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nScreening all children would \u201cidentify a number of children who are of very significant risk of premature heart disease,\u201d said Dr. William Neal of West Virginia University in Morgantown, who led the new study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe availability of cholesterol screening is not at issue.\n", "answer": 2}, {"article": "Nine rode exercise bikes in a gym to compare the sweat patches\u2019 performance with the decidedly lower-tech method of sweat-testing used today \u2014 taping on absorbent pads and carting the resulting wet samples to a laboratory.\nFor simple fitness purposes, it could give an early warning that it\u2019s time to replenish electrolytes before someone starts to feel dehydrated.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\nTogether, those measurements can indicate such things as hydration levels or electrolyte loss.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t describes the steps that need to be taken for this technology to become available to consumers and clinicians. Beyond calling the device \u201cexperimental,\u201d it gives no sense as to how close the device is to being marketed. \u00a0", "answer": 0}, {"article": "Additional co-authors include researchers from UCSF, the University of Texas at Austin, the University of Pittsburgh Medical Center, Virginia Commonwealth University, the Icahn School of Medicine at Mount Sinai, and University Hospital Antwerp, Belgium.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\nFor concussion sufferers, even those who never lost consciousness, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event, using a new non-invasive magnetic resonance imaging (MRI) method devised by a consortium of researchers led by UC San Francisco scientists.\n\"We asked subjects to close their eyes, to relax, and to not focus their attention on anything specific -- but also to not fall asleep,\" Mukherjee said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Compared to other imaging technologies like MRI and CT, fMRI is not as widespread, but it\u2019s becoming increasingly common as a diagnostic method to assess brain function. Most academic centers are equipped with fMRI machines, especially hospitals conducting neuroscience research.\nSince the news release doesn\u2019t discuss availability, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The author acknowledges that the initial clinical trial, in which the featured patient is participating, will take two more years and that that two additional clinical trials would have to demonstrate safety and efficacy of the drug before it could receive FDA approval. This was a strong point in the story.", "answer": 1}, {"article": "Although these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\nThe Agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release mentions that this drug is already approved for other uses and that the newly approved therapy is manufactured by Renaissance Lakewood for Serenity Pharmaceuticals.", "answer": 1}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job explaining what are basically three different approaches to varicose vein treatment: a surgical option, which is the most common; an injectable drug option, which is becoming more common; and the foaming injectable option, which some doctors use off label.", "answer": 1}, {"article": "\"CMS made the right decision,\" said John Petrini, a Santa Barbara, Calif., gastroenterologist who heads the American Society for Gastrointestinal Endoscopy.\nCurrently about half of Americans over 50 are screened for the disease; some shun traditional colonoscopy, which is the only way to remove polyps, because of its invasive nature.\n\"They got it completely wrong,\" he said.\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nThe prospects for significant expansion of the procedure, which is covered by a growing number of insurance companies, have collided with a large and unexpected roadblock.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly virtual colonoscopy is available. The story could have described how widely available the procedure is \u2013 for example, is it still only limited to large, academic or urban medical centers?", "answer": 1}, {"article": "PERMP was not measured in the SHP465-305 study.\nThe completion of SHP465-305 addresses an FDA requirement to evaluate the safety and efficacy of SHP465 in children and adolescents prior to filing a Class 2 resubmission of the medicine for FDA approval.\nExcept to the extent otherwise required by applicable law, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.\n\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\nWith a launch planned for the second half of 2017, Shire expects that SHP465, following potential FDA approval, will have three years of Hatch-Waxman exclusivity and at least three patents listed in the FDA Orange Book expiring as late as May 2029.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states the drug maker hopes to begin marketing the drug during the second half of 2017, after clearing FDA approval. We often look skeptically upon predictions of when a drug may be approved, especially when those predictions come from those with a vested interested, but this date seems far enough off that it won\u2019t raise false hopes.", "answer": 1}, {"article": "It is very healthy.\n\u201cIf they want to make more, they just build more factories.\u201d\n\nCraven describes the race to turn coconut water into a big market, like iced tea or energy drinks, as something akin to a gold rush.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\nThe healthiest fats, those found in olive and canola oils, contain more monounsaturated fats, which do not raise LDL cholesterol and might even help lower it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The sheer volume of people within the retail food industry who seem excited about this trend makes us believe that\u00a0a lot of stores are following this fad, which means coconut products are widely available.", "answer": 1}, {"article": "\"It is very big.\n\"This new technology has the potential to facilitate an easy-to-administer, noninvasive blood test that would allow us to count tumor cells, and to characterize the biology of the cells,\" said Robert McCormack, Veridex's head of technology innovation and strategy.\n\"The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,\" Toner said.\n\"The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy,\" the Veridex statement said.\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes a researcher saying it \u201cit will take at least five years before the test is on the market\u201d but treats that as a fait accompli. But the story doesn\u2019t make clear the staggering amount of testing that remains ahead.", "answer": 1}, {"article": "Jan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\nFor those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that\u00a0rifaximin\u00a0\u201cis approved by the FDA only for traveler\u2019s diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\u201d And it interviews a physician who\u2019s been using it off-label for the non-constipation form of IBS. But the story does not make clear how widely used it is.", "answer": 1}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nSome insurers might pay, but some might balk.\nThere's one other thing, the CDC says.\nFor the same reason, patients should get an HIV test periodically while on the drug.\nThat'll help avoid creating viruses resistant to the drug when patients miss doses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that Truvada is already on the market.", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nTwo years ago, the drug giant Pfizer, which sells the erectile dysfunction drug Viagra, licensed the European rights to Xiaflex from Auxilium for an initial payment of $75 million.\nWith its belated success, BioSpecifics has sold off its ointment business.\nBut the company hopes to begin late-stage trials of Xiaflex for Peyronie\u2019s disease later this year.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Xiaflex was approved last month and will go on sale later this month.", "answer": 1}, {"article": "A video of him walking with and without the system can be found at: https:/ .\nWith the technology switched on, he covered far more ground and his pace was twice as fast during his 30-week study.\nThe researchers are seeking funding to fit him with a permanent FES system in a clinical trial.\n\"We try to time the pattern to stimulation so that it's integrated with their ability.\nOnce we got it fine-tuned and I got walking, I thought it was amazing.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We would have liked to see discussion of what hurdles this technology must overcome to be made available to the general patient population, as well as what types of patients might stand to benefit.", "answer": 0}, {"article": "While median progression-free survival appeared similar between treatments (4.6 months and 4.4 months with nivolumab and everolimus, respectively), when researchers explored a delayed progression-free survival benefit at six months, they reported 15.6 months with nivolumab and 11.7 months with everolimus.\n\"Immunotherapy has long been believed to have the potential to make an impact in kidney cancer, but until now we had not been able to demonstrate such a significant survival benefit.\n\"The immune system has a memory, so even when treatment has stopped, the body continues to exhibit a long-term response - meaning these patients can live normal lives without progressive disease.\"\nThe median duration of treatment was 5.5 months with nivolumab and 3.7 months with everolimus.\n\"We're studying combination therapies to answer these questions and believe these studies will change the way we treat many cancers.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that \u201cNivolumab, marketed as Opdivo, is currently used to treat metastatic melanoma and advanced non-small cell lung cancer.\u201d\u00a0 However it is silent on the availability of everolimus (Afinitor). The release also did not mention insurance coverage for these treatments.", "answer": 0}, {"article": "Marion Nestle, a nutrition professor at New York University, says longer studies conducted among people in their own environments, not with such controlled meals, have shown \"little difference in weight loss and maintenance between one kind of diet and another.\"\nAdherence is the major key for weight loss and maintenance.\nExperts had different responses to the findings.\nThe dieters were admitted to the hospital four times for medical and metabolic testing.\nThat's about an hour of light physical activity,\" he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the 3 diets is not question.", "answer": 2}, {"article": "The study is published in this week\u2019s issue of the New England Journal of Medicine.\nAfter six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nAt least 5% of patients on the drug combination suffered from low white blood cell counts, fatigue, serious diarrhea, a loss of feeling in their feet and hands, as well as hair loss.\nOnly about 6 percent of those with the diagnosis live longer than five years.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the drugs was not discussed.\u00a0 This was a story about a French study.\u00a0 Are the drugs widely available in the US?\u00a0 The story never explained.", "answer": 0}, {"article": "The researchers split the participants into two groups, one that received drug treatment and one that took placebo pills.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\n\"It's a pessimistic trade-off, the weight gain and other side effects for what looks like a modest delay in the acute psychotic episode,\" said Dr. Steven Hyman, a professor of neurobiology at Harvard.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Zyprexa is not FDA approved for prevention of psychosis in patients identified at high-risk. The story mentions that this was a preliminary trial and explains that the idea of identifying patients at high-risk of developing a psychotic disorder and treating them with a drug like Zyprexa is still very new, controversial and has several risks, with very limited long-term benefit. ", "answer": 1}, {"article": "A family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\nAntidepressants may work better for certain types of IBS, and the study findings also suggest that the type of medication may matter, Kulak-Bejda said by email.\nWhile some people improve with customized diets that avoid certain foods that trigger symptoms, this approach doesn\u2019t help everyone and some emerging research suggests that the condition may also be influenced by processes in the brain.\n\u201cThe decision to use antidepressants as a form of therapy should be taken individually,\u201d Kulak-Bejda said.\nFor the current analysis, researchers examined data from 53 trials that compared the effects of antidepressants or psychotherapy, either alone or in combination, versus placebo treatments or \u201cusual management\u201d in people with IBS.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t specifically state that the antidepressants and treatment options studied in these various trials are available for clinical use. However, we think it can be broadly assumed that readers know these treatment options are available. As such, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "This suggested the test could be used to tell the conditions apart.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\nRather than testing for the presence of bacteria or virus, the researchers looked at the first tell-tale signs of infection: the cytokines produced by the patient\u2019s immune system in response to pathogens and other injury processes.\n\u201cWe have many tests for making diagnoses, but the ones that conclusively indicate infection can often take more time than we\u2019d like, especially in cases of childhood meningitis or encephalitis,\u201d said Mark Curtis, MD, PhD, Associate Professor of Pathology, Anatomy and Cell Biology, who also works as a hospital pathologist.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although a doctor\u2019s office test is teased, the release makes clear that it needs to be \u201cconfirmed with additional research.\u201d\nThere are a number of steps ahead before we know if this will indeed be available.", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In Finland, saunas are common. Since this story was published for a US audience, it should have included some mention of the relative abundance or scarcity of saunas here and where to find them. The story warned that the same benefits shouldn\u2019t be expected from hot tubs and steam rooms \u2014 a nice addition. As we mentioned above, the cost of access to sauna would have been a great addition to the story.", "answer": 0}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nAt the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We give credit here for this acknowledgment: \u201cThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s.\u201d However, readers overall may get the impression that the test\u2019s clinical usage is coming soon, when that\u2019s not likely the case. We\u2019d be much more comfortable if the story included more information accurately portraying the tentative nature of the findings, findings that might be actually caused by other factors not studied.", "answer": 1}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\nIt\u2019s called the biophilia hypothesis, and it argues that humans evolved a built-in need to affiliate with other living beings.\n\u201cKids with pets have less anxiety.\u201d\n\nThat\u2019s actually not what the study concluded.\n\u201cIt\u2019s a field that has been sort of carried forward by the convictions of practitioners\u201d who have seen patients\u2019 mental health improve after working with or adopting animals, said James Serpell, director of the Center for the Interaction of Animals and Society at the University of Pennsylvania School of Veterinary Medicine.\nYet the subject did not become a research target until the American child psychologist Boris Levinson began writing in the 1960s about the positive effect his dog Jingles had on patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that therapy animals are in widespread use, and offers numerous related examples. However, people may wonder how to get one, and whether their insurance would pay.", "answer": 1}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread use of c-sections is clear in the story. ", "answer": 1}, {"article": "Visit http://www.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nThe imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear if this software is already on the market or if it is in the early stages of development. Given that the study, which was presented at a conference, is subtitled \u201cAre We Ready for Prime Time?\u201d this is an issue that the researchers were planning to address \u2014 but no hint of that information is in the release.", "answer": 0}, {"article": "\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nFruits and vegetables are staples in a healthy diet, and that includes one aimed at preventing cancer.\nFarvid says that apples, bananas and grapes contain fiber, which could help to lower cancer risk; they are also high in flavonoids, which act as antioxidants to combat damage to cells that can trigger abnormal growth.\nWhile challenging, changing diet can be a relatively easy way to alter a woman\u2019s breast cancer risk equation, beginning even at a young age.\nTaken together, the results show how critical diet can be in modulating risk of breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fruit has been around longer than humans have, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nOramed uses a protective coating and a high-enough dose of insulin so that most of it can be destroyed and still deliver a clinically beneficial amount of the hormone.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\nThere were no reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar, the company said.\nWhile insulin is typically associated with type 1 diabetes, many patients with type 2 eventually see their disease progress to the point where they need insulin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug needs more research before it will be reviewed by the FDA for approval.", "answer": 1}, {"article": "While the mechanism behind the vision-cognition relationship isn\u2019t well understood, Zheng said, worsening vision can discourage people from brain-stimulating activities like doing crosswords and engaging with other people.\nWhile mental function at one check-up was also related to vision at the following exam, the effect of vision on subsequent mental function was significantly stronger.\n(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\n\u201cIf you\u2019re aging without good vision, not only are you giving your brain less stimulation, you might be altering your brain at a structural level,\u201d she said in a phone interview.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that the vision treatments mentioned (\u201ca new eyeglass prescription or surgery to remove cataracts\u201d) are available in the marketplace, which is accurate.", "answer": 1}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\nHe is a surgical oncologist at Northwell Health's Imbert Cancer Center in Bay Shore, N.Y.\n\n\"Not only did these patients have a better survival outcome at one year, but they had only one-third the side effects compared to Yervoy,\" Deutsch said.\nMONDAY, Sept. 11, 2017 (HealthDay News) -- New research suggests that Opdivo -- a drug that works with the immune system to fight melanoma -- is more effective than the current standard of care for patients who've had surgery to remove advanced tumors.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nAnd at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains: \u201cBoth Opdivo and Yervoy are already approved by the U.S. Food and Drug Administration to treat advanced (metastatic) melanoma. In some patients, the drugs are used in combination.\u201d", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 For patients whose hearing is considered \u201ctoo good\u201d for traditional cochlear implants, but whose hearing loss is too advanced to benefit from hearing aids, there hasn\u2019t been a device to meet their needs.\nNearly 25 percent of those ages 65 to 74 and 50 percent of those who are 75 and older have disabling hearing loss.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\n\u201cOur clinical trial participants were overwhelmingly receptive to this new technology,\u201d Pillsbury said.\nNinety-two percent of participants reported an improvement in their ability to hear even among background noise, one of the most challenging listening environments for people with hearing loss.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the device received FDA approval on September 16.and that it will be available \u201cin coming months.\u201d", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear this drug is still in development.", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells readers exactly where they can buy an Alex device, and notes that the Text Neck Indicator is an Android app that is already on the market.", "answer": 1}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\nSo there's a big variability in treatment effect.\nIt's just not as good as bypass.\"\n\"So bands are easy to sell and very heavily marketed,\" he added.\nFor more on gastric banding, visit the National Institutes of Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The gastric banding procedure was appropriately described as an available treatment.", "answer": 1}, {"article": "Electrical signals follow that nerve to areas in the brain where seizures often begin, researchers say.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\n\"For me it's extremely effective,\" says Jennifer Rees, 49, who lives in the Los Angeles area and has been using the nerve stimulator for six years.\nResearchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story that aired\u00a0said at the very end, \u201cThe device isn\u2019t approved by the FDA yet. That\u2019s probably several years off.\u201d The accompanying online version of the story said roughly the same thing. Readers should have been told that they are very unlikely to be able to have this device prescribed for them unless they can find their way into a clinical trial. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Researchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n\"If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change,\" says study author Margaret L. Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, in a news release.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story talks about \"women\u2019s T-score, which is a measure of bone density\", but it never explains how a bone density test is conducted or who might conduct it. Does a woman have to go to a specialist? What kind of equipment is involved? It doesn\u2019t take much to address these questions. ", "answer": 0}, {"article": "In a landmark medical clash pitting the diagnostic merits of fancy tech versus vintage exercise machines, the new toys and old ways finished in a dead heat, cardiologists reported Saturday.\nThe 10,000-plus patients, who visited 193 health centers in the U.S. and Canada, had no prior diagnosis of coronary artery disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nUntil this study, doctors have been \"guessing\" which form of those two diagnostic tests is best, Douglas said.\nBut one Cleveland Clinic patient epitomizes a difference between CTAs and stress tests \u2014 and he does so just by being alive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does not make information about availability explicit, it is reasonably clear from the story that both types of diagnostic tests are currently available.", "answer": 1}, {"article": "Griffith said a German study recently found that donated corneas cost about $2,500.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\nAs for side effects, Griffith said the patients didn't report any pain or discomfort, and there were no signs that their bodies tried to reject the corneas, a risk that people face when they get transplanted organs.\nAn estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nWEDNESDAY, Aug. 25, 2010 (HealthDay News) -- Swedish scientists report that they've successfully implanted \"biosynthetic\" corneas in 10 patients, potentially paving the way for more accessible treatment for those with cornea-related vision problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The only hint that this research is preliminary is toward the end when the story says, The next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients. This actually sounds actually more optimistic than the comments from Griffith in the press release, leading one to believe that she was more cautious than this sentence implies.", "answer": 0}, {"article": "A majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\nHaving trained EMS staff to administer naloxone in rural areas will save lives.\u201d\n\nTo reduce opioid overdose deaths, particularly in rural areas, CDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\nAs of 2014, only 12 states allowed basic EMS staff to administer naloxone for a suspected opioid overdose; all 50 states allow advanced EMS staff to administer the overdose reversal treatment.\nThe findings indicate naloxone was most likely to be administered to women, people between the ages of 20 and 29, and people living in suburban areas.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The major point of this release is that not enough EMS staff are administering the drug. It could have been made more clear that the drug is widely available for EMS staff, but that only a select few EMS staff can administer it in most states. But we think this passes the test.", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses two products that are available for purchase. It also notes that people who have purchased one of these devices may not even be able to bring it on a flight.", "answer": 1}, {"article": "Neither treatment prompted significant side effects, the authors said.\nHowever, while this approach is often successful in younger children (between the ages of 3 and 7), it is successful among only about a third of older children (between the ages of 7 and 12).\nAnd while theorizing that the apparent success of this alternative approach may have something to do with stimulating blood flow, retinal nerve growth and visual cortex activity, the authors acknowledged that the exact mechanism by which it works remains poorly understood.\nFor the latter group, doctors will often place a patch over the \"good\" eye temporarily in addition to eyeglasses, and treatment success is typically achieved in two-thirds of cases.\nBut for vision therapy this is the first I've heard of it, and I don't know that anyone has ever tried this before.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story\u00a0notes that acupuncture is more widely accepted in certain geographical areas than others, it doesn\u2019t convey how difficult a time people would have finding a skilled acupuncturist\u00a0across broad swaths of the country. This is especially important considering that the treatment was given 5 times a week and would be impractical\u00a0if significant travel time was required.\u00a0It also should have mentioned accreditation for\u00a0acupuncturists and how to choose a\u00a0practitioner.", "answer": 0}, {"article": "May 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nMore than half of people who took Xyrem reported at least a 30% improvement in pain, says Kim Dupree Jones, PhD, of Oregon Health & Science University in Portland.\nThe new study was presented at the annual meeting of the American Pain Society.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is not approved for use in fibromyalgia but is indicated for use in narcolepsy.", "answer": 1}, {"article": "She's on Twitter: @tarahaelle\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\nThe teens, ages 15 to 18 when the study began, had a body mass index (BMI) between 34 and 88, with half over 51.\n\"The potential impact of such risk reduction translates into a reduced likelihood of developing significant heart disease later in life, including atherosclerosis, heart failure and stroke,\" says study author Marc Michalsky, surgical director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio, in an email.\nThe risk factors measured in the study included elevated blood pressure (above 120/80 mg/Hg), high cholesterol, high insulin levels in the blood and abnormally high levels of C-reactive protein, an indicator of inflammation in the body.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that 1,600 teens undergo stomach reduction surgeries each year, which suggests that they are widely available. It also mentions the need to seek counseling and \u201cdetailed information from well-established bariatric surgery centers that are specifically dedicated to treating adolescents.\u201d\nHowever, one big key to availability is insurance coverage\u2013and this was not mentioned.", "answer": 1}, {"article": "\"Now that we have demonstrated safety in this small clinical trial, we are in a position to find out if the health benefits that we have seen in animals can be reproduced in people,\" says Brenner, who also is co-director of the Obesity Research and Education Initiative, professor of internal medicine, and a member of the Fraternal Order of Eagles Diabetes Research Center at the UI.\nThe information from the mouse study subsequently helped Brenner's team design the formal clinical trial.\nNR was also the best of the three in stimulating the activity of sirtuin enzymes.\nPrior to the formal clinical trial, Brenner conducted a pilot human study - on himself.\nThe trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that the supplements are commercially available.", "answer": 1}, {"article": "D'Amico, chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, N.J.\nAs bariatric surgery has grown more common (some 144,000 such procedures were performed in the United States in 2004, more than double the number in 2002), D'Amico says, patients seeking body contouring have \"started to show up in plastic surgeons' offices in large numbers.\"\nThe skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\n\u00b7\n\nRanit Mishori, a family medicine resident at Georgetown University/Providence Hospital, wrote recently for the Health section about the growth in the use of cochlear implants.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says this has been \u201ca hot topic at all the national conferences over the last couple of years\u201d. It is unclear as to whether this indicates that there are lots of adequately trained plastic surgeons who are trained for these types of procedures or whether it is only available at certain centers. It is perhaps telling that one plastic surgeon interviewed stated that the increase in need for surgical revisions required after contouring procedures is because there are surgeons who \u201clack adequate experience\u201d. The article would have been much more valuable to readers if it had provided some guidance for how consumers might evaluate the skill and proficiency of a plastic surgeon they were considering consulting for this type of work. ", "answer": 0}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nThe drug is not for women whose prior premature births were of twins or other multiple births, or who are carrying more than one fetus in their current pregnancy.\nThe study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.\nIn 1956, the FDA approved 17-HP for the treatment of certain cancers and other hormonal disorders, under the brand name Delalutin.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story is FDA approval of the drug.", "answer": 1}, {"article": "This was a phase 2 trial.\n\"Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3.\"\nIniparib inhibits a pathway that helps repair DNA; researchers call it the poly(ADP-ribose) polymerase (PARP) pathway.\nWEDNESDAY, Jan. 5, 2011 (HealthDay News) -- Researchers have taken another step in the hunt to find a treatment for an aggressive, likely-to-recur form of breast cancer.\nMore than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug is experimental & that the results reported are from a Phase 2 trial.\u00a0 Results from a larger Phase 3 trial of 500 women will be available in 2-3 months.\u00a0 Information about whether the drug has FDA approval or whether it is currently used for treating other diseases would have been helpful.", "answer": 1}, {"article": "Of the 741 people who joined his experiment from 2005 to 2015, 227 (202 of them women) followed through with doing the 12 assigned yoga poses daily or at least every other day.\n\u201cYoga looks like it\u2019s safe, even for people who have suffered significant bone loss,\u201d Dr. Fishman said in an interview.\n\u201cYoga puts more pressure on bone than gravity does,\u201d he said in an interview.\nA pharmaceutical company is unlikely to fund a study that doesn\u2019t involve a drug, and in any event, the research requires a large group of volunteers tracked over a very long time.\nBefore the study, the participants had had 109 fractures, reported by them or found on X-rays.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga is everywhere (the phrase \u201912 important yoga poses\u2019 gives 6.2 million hits on google).", "answer": 1}, {"article": "EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, AUGUST 5, 2015\n\nMedia Advisory: To contact corresponding author Gretchen A. Brenes, Ph.D., call Marguerite Beck at 336-716-2415 or email marbeck@wakehealth.edu.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nGeneralized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the telephone is ubiquitous in modern life, one assumes that such a program as explained in this clinical trial could be available in short notice, assuming financial support for the project.", "answer": 1}, {"article": "The scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\nThe heightened connectivity to spirituality has also been demonstrated to curb suicidal thoughts and attempts.\nThe UAB isn't the first study to flirt with this idea.\nOf those surveyed, 13.6%, or about 27,235 people, reported having used classic psychedelics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study noted that the drugs are not available legally in the United States.", "answer": 1}, {"article": "In the two-part study, Maciejewski's team first looked at the results of about 1,800 men and women who had gastric bypass surgery.\nThe new finding, he added, validates his belief that the gastric bypass could be a \"durable procedure.\"\nThe average age of the men and women studied was about 52, and three-quarters were men.\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\n\"This study suggests that patients interested in bariatric surgery, especially gastric bypass surgery, should be able to lose a significant amount of weight and keep that weight off for a very long time,\" said study researcher Matt Maciejewski.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make it readily clear how accessible these surgeries are, and who is a good candidate for one. Typically, these procedures are for people over a certain body-mass index, for example. And insurance coverage may or may not pay for it.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).\nThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cFDA\u2019s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Whether or not this medication will be covered by insurance is a huge concern. Its high cost will affect how many people can access this new drug. Its availability should have been addressed in the release.", "answer": 0}, {"article": "\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\nThe study appeared online May 13 in The Annals of Rheumatic Diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nMost readers will be familiar with the \"availability\" of breast-feeding. \n", "answer": 1}, {"article": "This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\n\"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season.\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the Fluzone high-dose vaccine used in the study was approved by the FDA in 2009.\nA booster dose would currently be considered an \u201coff label\u201d use and may not be covered by insurance.", "answer": 1}, {"article": "That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection.\nResearch presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.\nOn the other hand, people whose physical activity level had declined after their diagnosis had higher death rates from lymphoma and other causes than those who had not changed their level of physical activity.\nThe American Cancer Society has more on lymphoma.\nThrough periodic questionnaires, the researchers tracked the participants' physical activity levels from before their cancer diagnoses until three years afterwards.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It can be assumed that readers are aware of their options regarding physical activity.", "answer": 2}, {"article": "MONDAY, Aug. 15, 2011 (HealthDay News) -- A traditional Chinese herbal treatment may reduce fever from H1N1 (\"swine flu\") influenza just as well as the prescription medication Tamiflu, a new study suggests.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nThe results: Both M-Y and Tamiflu were effective at eliminating fever, whether administered on their own or in combination.\nAll three approaches helped to resolve fever sooner than no intervention whatsoever, the authors said, noting it appeared that fever dissipated fastest when M-Y and Tamiflu were given together.\nOne group was given 75 milligrams of Tamiflu twice a day in capsule form; a second group received 200 milliliters of M-Y four times a day in liquid form; a third group took the same dosages of Tamiflu and M-Y together; and a fourth group received no treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The description of the herb mixture\u2019s availability is good enough for a satisfactory. The story says that \u201cfinding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\u201d\u00a0 The story could have noted that ephedra\u2019s use remains\u00a0legal in traditional Chinese medicine (the application being discussed in this story), but patients may\u00a0only obtain the medicine through\u00a0a Chinese medicine practitioner.", "answer": 1}, {"article": "\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nThe disease most often strikes adults after age 20, but it can develop in children.\nHowever, few foods naturally contain the vitamin.\nVitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nMS is a nervous system disease that attacks the material, called myelin, that covers nerve fibers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lists common sources of vitamin D, all of which are widely available.", "answer": 1}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\nThis abstract can be found at sirmeeting.org\n\nThe Society of Interventional Radiology is a nonprofit, professional medical society representing more than 7,500 practicing interventional radiology physicians, trainees, students, scientists and clinical associates, dedicated to improving patient care through the limitless potential of image-guided therapies.\n\"This is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.\"\nLOS ANGELES (March 21, 2018)--Advanced stage liver tumors may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to a study presented today at the Society of Interventional Radiology's Annual Scientific Meeting.\nS. Raman; M. Pless; A. Cubillo; A. Calvo; R. Hecht; C. Liu; E. Chan; J. Chesney; A. Prat; David Geffen School of Medicine, University of California, Los Angeles, CA;, Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland; HM Universitario Sanchinarro, CIOCC, Madrid, Spain; Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made it clear that this therapy is still being tested and people with liver cancer should not expect to access it soon except through a clinical trial:\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned. Additional investigation is also planned to test the therapy in combination with a checkpoint inhibitor to activate a stronger immune response.\n\u201cImage-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,\u201d said Raman. \u201cThis is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.\u201d", "answer": 1}, {"article": "The drug briakinumab reduced psoriasis symptoms by at least 75 percent in nearly 82 percent of those taking it, compared to just 40 percent of those on methotrexate.\nThe disease causes patches of thick, red, inflamed skin that have silvery scales.\nAn ongoing three-year trial involves 248 people from the current study.\nResearch on briakinumab is continuing.\nThe study was funded by the drug's manufacturer, Abbott Laboratories.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of briakinumab was made clear in the story.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Women who take bone drugs for several years have a slightly increased chance of suffering an unusual type of thigh fracture, according to a large Canadian study.\nThe majority are postmenopausal women.\nThe risk of a thighbone fracture differed depending on how long the women had been taking the medicine.\nTheir findings appear in the Journal of the American Medical Association.\nThat works out to nearly three times the risk of those who\u2019d taken the drugs for roughly three months or less, after accounting for other risk factors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that these drugs are widely available.", "answer": 1}, {"article": "The Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\nIf the berries are not cooked thoroughly they can be poisonous.\nAn ancient herbal remedy is getting fresh attention this cold and flu season.\n\"The duration and the severity of how they get sick is much less and they get healthy quicker,\" he said.\nRaw or unripe elderberries, as well as other parts of the plant, contain a toxic compound related to cyanide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It seems clear from the story that elderberry extract is readily available.", "answer": 1}, {"article": "Still, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\n\"Some of the people are now out 44 months and still remain free of disease,\" Urba says.\nWhile far from a cure, the treatment is the first to improve survival in people with melanoma that has spread, or metastasized, says Dr. Walter Urba, director of cancer research at the Providence Cancer Center.\nSome patients received ipilimumab alone, others it combined with a cancer vaccine called gp100, and a third group received only the cancer vaccine.\nThe antibodies temporarily jam the switch, allowing T cells to continue attacking cancer tissue for weeks or months \u2013 for as long as patients continue to receive injections of the engineered antibody.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the approach is experimental.\u00a0 The story also states:\nMinor quibble:\u00a0 perhaps the story should have reminded readers that a drug company\u2019s timetable predictions may not be the most reliable. \nFor local readers it explained: ", "answer": 1}, {"article": "Psychological factors or lifestyle factors may play a role, he said.\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\n\"But for about a third [of patients], biological issues are at play, such as not easily experiencing satiety signals from the gut to the brain, which senses what your energy intake has been,\" he said.\nMONDAY, Oct. 15, 2012 (HealthDay News) -- A prescription medication originally developed to treat epilepsy may help obese adults shed weight when combined with routine nutritional counseling, researchers say.\nAlthough nearly 55 percent of those on the higher-dose medication shed 5 percent or more of their pre-study weight, that figure was 34 percent among the lower-dose group and 31 percent among the non-medication participants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that zonisamide is already used as an anti-seizure drug.\u00a0 It did not discuss whether it\u2019s used off-label for weight loss.\nFrom an availability perspective, it also didn\u2019t provide enough detail about this statement:\n\u201cAll study participants followed their treatment plan for one year. During this time, they all also received monthly individualized nutritional counseling, which Gadde described as \u201cnot intensive,\u201d to help them reduce their overall caloric intake.\u201d\nWhat does \u201cnot intensive\u201d actually mean?\u00a0 Since this was part of the treatment \u201cpackage,\u201d how generalizable is this approach?\u00a0 What kind of setting would be capable of delivering it?\u00a0 The vague \u201cnot intensive\u201d comment just isn\u2019t helpful at all.", "answer": 0}, {"article": "Those studies are expected to launch later this year, including two at Penn.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\n\"This study provides evidence that some patients can have long-term disease control with this drug, which we haven't seen before,\" Alley said.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Mesothelioma patients would want to know if the drug is available for them and that\u2019s not the case here. As used in a phase 1b study the drug is considered experimental.\nWe are told that this treatment is used for other types of cancer so presumably it\u2019s on the market. There may be a risk that some oncologists will see the release and use the drug \u201coff label\u201d for mesothelioma, since it is available for other conditions.", "answer": 0}, {"article": "(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nInsufficient levels of circulating T in men, contributes to frailty and bone loss.\nIn addition, T is essential for overall health and well-being and for the prevention of osteoporosis.\nIn men, T plays a key role in the development of male reproductive tissues as well as promoting secondary sexual characteristics such as increased muscle and bone mass and growth of body hair.\nThe researchers followed a group of men for eight years who had been on TTh and compared them with another group of men who remained untreated for the same time period.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Testosterone treatment is clearly available although topical preparations are more expensive than injections and insurance companies may balk at covering these treatments.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn about one French doctor using this approach in London.\u00a0 We are given no sense of whether anyone else is doing this or where. ", "answer": 0}, {"article": "Kjersti Aagaard, vice chair of obstetrics and gynecology at Baylor College of Medicine and Texas Children's Hospital, is more skeptical.\n\"The most important thing for parents to be talking with their provider about is how will we adapt to the delivery as it emerges,\" she said.\nIn the new study, Andersson found that healthy, full-term newborns whose umbilical cords were left attached for three extra minutes had better fine motor control when they reached preschool than those clamped immediately.\nMany countries and professional organizations, including the American Congress of Obstetricians and Gynecologists, have called on obstetricians to delay cord clamping in premature babies when feasible.\nBut those doctors overestimated the benefit to the mother and didn't look at the impact their change had on the babies, said Heike Rabe, a researcher at Brighton and Sussex Medical School and University Hospitals, in the United Kingdom, who wrote an editorial accompanying the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hypothetically, a delay in cord-clamping is something equally available to all those who deliver babies and their patients. But in the real world it\u2019s different:\u00a0A delay is only available to a woman\u00a0if her\u00a0doctor/health system decides to offer it (barring the role of patient advocacy). The story didn\u2019t explore how common delayed cord-clamping is, or how willing doctors are to consider it. But since the story does at least suggest that women can raise the issue with their doctor and make a shared decision about what to do, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Among the children born during the study, Pan and his colleagues found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n\u201cPreventing mother-to-child transmission is the most effective way to reduce the global burden of chronic hepatitis B infection and liver cancer,\u201d says Calvin Pan, MD, lead author of the study and a clinical professor of medicine at NYU Langone.\nThose with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it\u2019s available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B.", "answer": 2}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\n\"I think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments,\" Borges says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "No information in the news release gives an indication as to when (or if) tucatinib might be widely available.\nThe lead researcher\u2019s comment that \u201cI think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments\u201d is problematic given that the investigative drug is still in early trials and has not yet been FDA approved. ", "answer": 0}, {"article": "Disease-free survival and overall survival three years after treatment were 48.3% and 55.8%, respectively.\nResearchers say surgical removal of tumors is the standard treatment for early-stage lung cancer, but some people are not candidates for surgery due to other coexisting illnesses such as emphysema and heart disease.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nIn these situations, the lung cancer tumor is deemed inoperable and conventional radiation therapy or observation without cancer treatment is offered.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that SBRT is not FDA approved and is still \"experimental\" and in clinical trials. The story could have provided some information on how someone with inoperable lung tumors\u00a0could get access to the clinical trial. ", "answer": 1}, {"article": "She told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\n\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\nThe medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\nFor the first time, researchers have shown that gene therapy can be used to improve vision for blind children and young adults.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explain that the procedure is not ready for general application.\u00a0 It does not make clear\u00a0 that this is part of an on-going clinical trial currently recruiting study subjects.\u00a0 Instead, it referred to the experiment as \"a medical milestone\" and as \"a cutting-edge therapy.\"\u00a0 It\u2019s not yet a therapy.\u00a0 It\u2019s an experiment. \n\u00a0", "answer": 0}, {"article": "MONDAY, Oct. 10, 2011 (HealthDay News) -- An experimental Alzheimer's disease drug, gantenerumab, may help lower levels of amyloid plaque in the brains of people with the disease, an early clinical trial indicates.\nAlzheimer's disease is the most common form of dementia.\nThe higher dose yielded greater reductions in amyloid levels, the study showed.\n\"They are all extremely exciting and promising in animals,\" he said.\nFor more information about Alzheimer's disease signs, symptoms and treatments, visit the Alzheimer's Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The early, experimental stage of the research was clear in the story.", "answer": 1}, {"article": "Previous research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\nThe St. Jude Medical Neuromodulation company, which has provided consulting fees to Mayberg and some of the other study authors, is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression, Mayberg said.\nThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\nStill, he said, it's important to note that \"we seem to be making progress and hopefully those who are suffering the most can find solace in that and not give up hope.\"\nStill, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is widely available, saying, \u201cDeep brain stimulation has been around for more than 20 years\u2026and is commonly used to treat Parkinson\u2019s disease.\u201d", "answer": 1}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nSome think it has potential as an add-on or alternative to standard treatment, while others argue any acupuncture-related benefits are likely the result of hopeful patients getting treatment they strongly believe will help them.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is mainstream enough to be available in\u00a0metropolitan areas, those living in rural places will often\u00a0have a tough time finding a licensed and qualified practitioner. Although the story could have been more emphatic on this point, it does\u00a0mention\u00a0the \u201cinconvenience of getting to a clinic\u201d as one of the main downsides of therapy. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Accessed October 2013 from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.jsp [5] Flum, D. R., et al.\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\n[3] The risk of death is about 0.1 percent[4] and the overall likelihood of major complications is about 4 percent.\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that the Obalon device was approved by the FDA in September, so readers might be able to guess that it will be available in the U.S. relatively soon. The release could have noted that the manufacturer will start selling it in this country in January 2017, and that it has been on the market in Europe and other countries for almost three years.", "answer": 1}, {"article": "Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nIn addition, there were differences in the measured absolute amounts of exercise performed when comparing objective activity monitoring using a wearable \"device\" and self-report of physical activity.\nFor the LIFE study, the researchers analyzed data from 1,635 men and women age 70-89 over an average of 2.6 years.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The program of exercise training used in the study is not well described but is presumably within the scope of many senior centers and exercise programs designed for the elderly population. The release would ideally have made it clear that the program was not unique and is likely widely available.", "answer": 2}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\n\"There has been great interest in developing stents coated with alternative drugs and different polymers,\" he explained.\nHowever, they said a limitation of their study is the one-year follow-up period, and noted that a longer, ongoing study pitting zotarolimus-eluting stents against sirolimus-eluting stents will provide more safety information.\nThe trial was partially funded by Medtronic, maker of the zotarolimus-eluting stent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article could\u2019ve been more explicit about the availability of these 3 stents, but the last sentence describing the study\u2019s\u00a0real-world implications,\u00a0suggests that all 3 are currently available in cath labs.", "answer": 1}, {"article": "\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nDepression is about three times more common in heart attack survivors and those hospitalized with heart problems than the general population, according to the recommendations published in the journal Circulation.\n\u201cSome physicians are qualified to treat it \u2014 others may be more comfortable referring the problem to a qualified mental health professional,\u201d Froelicher said.\nThe authors said only about half of heart doctors say they treat depression in their patients \u2014 and not all those diagnosed with depression are treated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly depression screening is available but not as widely used as it should be in the context of heart disease patients.", "answer": 1}, {"article": "\u201cThe big question is, how can we make sure that everybody responds?\u201d\n\nThe Duke team compared their 61 volunteers to similar past patients who did not get the treatment.\nThe patient who had the hemorrhage suffered aphasia but was still alive more nearly five years later.\nAll but one of those previous patients died after an average of 11 months.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\nBut there\u2019s evidence that some viruses can home in on tumors and kill them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment and is not widely available.", "answer": 1}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nThe study, however, has some limitations, Bernik noted.\nNearly 36 percent of these women had never had a mammogram.\nThe study appears online Dec. 6 in the journal Cancer Epidemiology, Biomarkers & Prevention.\n\"This study focuses on survival.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The study was in the Netherlands, which has a national screening program.\n\u00a0", "answer": 2}, {"article": "\"Great.\nInspire is not for everyone.\nMy thought process had gone,\" said Peggy Siravo.\nHer memory got so bad, her family thought she had dementia.\nThey ran tests throughout the night.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that Inspire is available.", "answer": 1}, {"article": "\"The consistency among the results lead to the unequivocal conclusion that there is no clinical benefit of the use of folic acid and vitamin B12 (with or without the addition of vitamin B6) in patients\" with heart disease, wrote Joseph Loscalzo of the Brigham and Women's Hospital in Boston in an editorial that will be published with the studies.\nAgain, while those receiving the supplements had lower homocysteine levels, they were no less likely to have another heart attack or a stroke, or to die from heart disease.\nAlthough homocysteine levels among those taking the supplements fell, they were no less likely to die from a heart attack or stroke, the researchers found.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nInstead, they looked at whether B vitamins can treat or reverse heart disease in people who already have it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that B vitamins have been in use for some time by many people for these purposes. ", "answer": 1}, {"article": "\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nThe revised guidelines are expected to reduce the cost of screening, the cost per life saved and overall deaths from prostate cancer.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nAnother approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\n\u201cEven long-distance bikers do not have prostate trauma\u201d that causes their PSA to increase, Dr. Carter said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that most men over 40 know that the PSA test is widely used for prostate cancer screening.\u00a0 ", "answer": 1}, {"article": "However this does not help them to overcome their fear in the long term.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\nOf all patients referred, four-fifths (79%) went on to have dental treatment without the need for sedation and 6% had their dental treatment under sedation.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that CBT and sedation are both available to patients with dental fears in the U.K. The release would have been stronger if it had noted, as the journal article does, that: \u201cSome barriers to the broader dissemination of CBT for people with dental phobia seem to remain, e.g. there is a lack of training and a skilled workforce to deliver the techniques.\u201d", "answer": 1}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nThe findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.\nIn all of these transplant-only patients, the transplants produced remissions, but more than a quarter of them relapsed within just 10 months.\nIn the experimental T-cell therapy tested in this trial, certain T cells from each patient's transplant donor were genetically engineered to produce receptors that allowed the T cells to recognize, very specifically, a target molecule called WT1.\nThe study was supported by funding from the National Institutes of Health and spinoff Juno Therapeutics, of which Greenberg is a scientific co-founder.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release reports that this is the first test of this particular treatment, so it is clear that it is just at the beginning of the research process.", "answer": 1}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n\"But our findings suggest that targeting the earliest risk markers of autism -- such as lack of attention or reduced social interest or engagement -- during the first year of life may lessen the development of these symptoms later on.\"\nTHURSDAY, Jan. 22, 2015 (HealthDay News) -- A therapy involving \"video feedback\" -- where parents watch videos of their interactions with their baby -- might help prevent infants at risk for autism from developing the disorder, a new study suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although there is no mention of where and when the potential therapy might be available, the story did establish that more research would be needed before it should be used. Since the story didn\u2019t give the impression that anyone should use this approach right now, we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "Data suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nNearly half of women taking flibanserin (and nearly a third of women taking placebo) reported at least minimal improvement in \"bothersome decreased sexual desire.\"\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indirectly informs that reader that flibanserin is not available by noting that it is in phase III clinical trials and that the manufacturer\u00a0is seeking FDA approval (despite early direct to consumer marketing campaigns).\u00a0 ", "answer": 1}, {"article": "Nov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish is not in question.\n ", "answer": 2}, {"article": "Is a drug really needed for what seems like a trivial use?\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\nOraVerse does the opposite, dilating the blood vessels and speeding up blood flow so the anesthetic can be carried away.\n\u201cWe aren\u2019t reversing the local anesthesia,\u201d said Dr. Paul A. Moore, chairman of anesthesiology at the University of Pittsburgh School of Dental Medicine, who is an adviser to Novalar.\n\u201cIt is reversing the epinephrine.\u201d\n\nThe label for the hypertension drug phentolamine contains warnings about heart attacks and occlusion of blood flow to the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article says the company that makes OraVerse, which has just been approved by the FDA for use in speeding the return of sensation after local dental anesthesia, expects to be selling it by the end of the year. ", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that pomegranates are now \u2018everywhere\u2019. There has been an increased number of pomegranate-containing products available in grocery stores and other venues. However, the article mentions that there have been few good clinical studies with pomegranates and that the results from those few studies should be followed up with larger, better studies. ", "answer": 1}, {"article": "The researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nBut women who consumed the most blueberries and strawberries had a 32% reduced risk of heart attack compared with the women who ate berries once a month or less.\nDuring the study the women experienced 405 heart attacks.\nFor 18 years, the women filled out surveys detailing their diets at four-year intervals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question.", "answer": 2}, {"article": "Newswise \u2014 WINSTON-SALEM, N.C. \u2013 Sept. 28, 2016 \u2013 Hot flashes \u2013 the bane of existence for many women during menopause \u2013 can be reduced in frequency by almost half for about 50 percent of women over eight weeks of acupuncture treatment, according to scientists at Wake Forest Baptist Medical Center.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\nHis spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\n\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture isn\u2019t a new idea, and many \u2014 if not most \u2014 readers would be familiar with the concept and aware of its availability. If this were a news story, we would like to see some discussion of how accessible acupuncture is. For example, one can be fairly certain of acupuncture practitioners being located in New York City. Whether one would be able to find certified practitioners in rural areas is less clear. However, we don\u2019t think that\u2019s an issue that needs to be addressed in a news release from a research hospital.", "answer": 1}, {"article": "The procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\nBut the first to reach an infant born by cesarean section come mostly from the environment \u2014 particularly bacteria from inaccessible or less-scrubbed areas like lamps and walls, and skin cells from everyone else in the delivery room.\n\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nThe small proof-of-principle study suggests a new way to inoculate babies, said Dr. Maria Gloria Dominguez-Bello, an associate professor of medicine at New York University and lead author of the report, published on Monday in Nature Medicine.\n\u2022 Let Me Tell You About My Big Baby\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that this is not widely used among medical professionals but that women are sometimes doing it on their own or \u201carranging\u201d to have it done. Given the potential risks of colonizing a newborn with less than friendly bacteria, we think that the story\u2019s suggestion (and implicit encouragement) for women to do this on their own are unfortunate. \u00a0The study was intended to determine if newborns could be colonized artificially and not to study the effects in later life.", "answer": 1}, {"article": "Researchers from the National Institutes of Health and Johnson & Johnson at the International AIDS Society conference in Paris Monday morning presented data on a clinical trial of what\u2019s called the \u201cAd26-env mosaic vaccine.\u201d\n\nThe mosaic vaccine was developed using a computer algorithm to analyze HIV data from around the world and select a range of HIV sequences to include in a shot.\nThe mosaic vaccine was the best tolerated and also capable of generating anti-HIV immune responses in all the people who received the shots.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\nIt\u2019s called a \u201cmosaic\u201d because it involves taking pieces of different viruses and sticking them together to generate immune responses that can cover a broad range of HIV subtypes.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear the vaccine is still in development and not likely to be available any time soon.", "answer": 1}, {"article": "The average age of the participants was 11.\n\"This receptor has several effects, but one of them may be to modulate the calcium inside and outside the neuron, which is very much related to the excitability of nerve cells,\" he explained.\n\"There is a fairly active and vocal group of families in Colorado who are using cannabidiol oils that are made artisanally,\" she said.\n\"This was a very, very treatment-resistant group, and the response was very promising,\" Devinsky said.\nA second study from the University of California, San Francisco, explored the long-term effectiveness of cannabidiol for children with epilepsy, by adding the marijuana-derived oil to the regular drug regimen of about 25 kids for one year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One of the study investigators makes\u00a0it clear that federal approval for the drug could take up to five years.\u00a0 However, the story also notes that some activist families have already begun using cannabidiol oils \u201cthat are made artisanally.\u201d", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the story\u2019s discussion, it is clear that all of the options being discussed in the story are available.", "answer": 1}, {"article": "LONDON (Reuters) - In an analysis that set off a fierce debate over the health effects of salt, researchers said on Wednesday they had found no evidence that small cuts to salt intake reduce the risk of developing heart disease or dying prematurely.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\n\u201cThe people in the trials we analyzed only reduced their salt intake by a moderate amount, so the effect on blood pressure and heart disease was not large,\u201d he said.\nThe researchers said they suspected the trials conducted so far were not big enough to show any benefits to heart health, and called for large-scale studies to be carried out soon.\nHigh blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of salt is not in question.", "answer": 2}, {"article": "But another experiment got the researchers more excited.\nThe main gene is called PI3K and it affects a pathway of other genes, Bild, Avrum Spira of Boston University and colleagues reported.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\nWASHINGTON (Reuters) - Researchers have identified a group of genes that are especially active in lung cancer patients \u2014 even in healthy tissue \u2014 and said they may be used to predict which smokers will eventually develop lung cancer.\nAnd it can be found in the windpipes of smokers, meaning they do not need more dangerous and uncomfortable lung tests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This genetic test is not yet available, but the story could have been clearer on that point. The story suggests there is no question regarding the availability of myo-inositol; however, more information on the specific formulation used in the study, as well as the dosage would have been useful. ", "answer": 1}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nAfter all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nT-cells are located in lymph nodes and blood, as well as in peripheral tissues such as skin and lung.\nScarification was first used nearly two centuries ago to give the first smallpox vaccinations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was not at all clear from the story whether anyone still uses the skin scratch \u2013 or scarification \u2013 method of vaccine delivery. ", "answer": 0}, {"article": "Doctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\n\u201cI\u2019m a language therapist,\u201d she said, \u201cbut I can\u2019t even think of the word to describe how much better this has made my life.\u201d\n\nAcross the country, about 24 million people suffer from asthma.\n\u201cThis isn\u2019t a cure, but it is definitely a breakthrough,\u201d said Dr. Pratik S. Patel, director of Interventional Pulmonary Medicine at Newark Beth Israel Medical Center in New Jersey.\n\u201cFor those of us in the field who work with severe asthmatics and see how limited they are, it\u2019s frustrating because we have this new therapy, we\u2019ve seen it work, and the data says it works,\u201d said Dr. Roy St. John, a pulmonary disease specialist at Columbus Pulmonary and Critical Care in Ohio.\nAfter the procedure, the airways no longer are so prone to constricting, studies show.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story states that about 650 people have been treated, and although it discusses lack of insurance coverage, it never explicitly explains how widespread is its availability.\u00a0 Do only high-tech teaching hospitals provide it?", "answer": 0}, {"article": "No woman who had a mastectomy developed breast cancer during the three years of follow-up testing.\n\u201cMost of these women will die of ovarian cancer, so you can save 20 percent of them with the prophylactic surgery,\u201d Kaklamani said.\nAccording to the American Cancer Society and the International Agency for Research on Cancer, 1.3 million new breast cancer cases are diagnosed around the world every year and it kills 465,000 women annually, making it the leading global cancer killer of women.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\nCHICAGO (Reuters) - Women with mutations in the well-known BRCA1 or BRCA2 genes who have their breasts and ovaries removed are much more likely to survive than women who do not get preventive surgery, U.S. researchers said on Tuesday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "\"Right then, I thought, \u2018Oh, why did I do this?\nHe warns people that there is a risk the implant will not work and that they may need to have it replaced if it stops working.\n'\u201d\n\nBecause the sounds generated by cochlear implants are different from sounds received naturally by the ear, it takes time to learn to interpret what they mean.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\nIn the meantime, he hopes to inspire others like him to get cochlear implants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story fails to explain whether cochlear implants are an FDA-approved device or widely available, or if trained personnel are widely available who can identify appropriate patients for the devices and surgically implant them.", "answer": 0}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nMore work needs to be done to confirm these findings.\nA new meta-analysis in the Journal of Clinical Sleep Medicine analyzed 18 studies on start times.\nThe studies mostly used self-reported measures of sleep duration.\nThere\u2019s some evidence that when students sleep better, they perform better in school as well.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that\u00a0few schools have modified their start times in response to this issue. A\u00a0map is a great addition in this regard.", "answer": 1}, {"article": "Newswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nBy early 2015, the disease had nearly killed him, despite surgery, radiation and chemotherapy.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nWithin six weeks of that first infusion, more than one-third of the cancer throughout his body was gone, and today, more than 90 percent of his tumor mass has disappeared.\nThe approval as a first- and second-line therapy \u201cis a really big deal,\u201d said Nghiem.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this is the first therapy approved by the FDA for this particular type of cancer once it has spread.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe technique and length of EarWell treatment varies according to the type and severity of the infant's ear deformity.\nThe EarWell system is a relatively simple technique for molding and reshaping the ear, taking advantage of the increased malleability of the ear cartilage in newborns.\nComplications consisted mainly of skin injuries that healed without further problems.\nFor most infants in the study, both ears were treated, for a total of 303 ears.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the EarWell system is not new and is already in clinical use.", "answer": 1}, {"article": "Many practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\nOver a six-week process, registered dietitians educated and monitored the progress of more than 90 IBS patients.\nThere was also more improvement of other bothersome symptoms compared to the control group: bloating, diarrhea and stool urgency.\n\u201cLow-FODMAP is not a new treatment, but we are now convinced that it really works,\u201d she says.\nAnd unfortunately there is no cure.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Information about the low FODMAP diet is widely available online.", "answer": 1}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the effort \u201cis still many years from yielding a marketable treatment or even starting human testing\u2026The drug may not enter human clinical trials for up to five years.\u201d", "answer": 1}, {"article": "\u201cIt was like how can I make it through this day because I am so tired?\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nI thought since I'm older so that's what it is.\u201d\n\nIt wasn\u2019t until a mother-daughter vacation that Turner\u2019s daughter noticed something interesting when her mother slept.\n\u201cAnd then the doctors looked piece by piece, and realized that what I have is sleep apnea.\u201d\n\nTurner\u2019s nightly interrupted breathing increased her chances of heart attack or stroke by three to four times, according to Dr. Robson Capasso, associate professor of Otolaryngology Head and Neck Surgery at Stanford University.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that the implantable pacemaker-like device was \u201capproved by the Food and Drug Administration in 2014.\u201d This is sufficient, but it\u00a0would have been helpful to know what types of doctors do the procedures and how widely it\u2019s offered.", "answer": 1}, {"article": "A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\n\"While more research is needed, the hope is such a tool could one day be used on the sidelines to help determine more quickly whether an athlete needs further testing.\"\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\nThe American Academy of Neurology, an association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The second half of the news release discusses through comments of sources the need for further research to explore the utility of the device. That type of content sends the message\u00a0to readers that the technology is not yet available. We do have concerns with the language suggesting that this technology should be readily available at sporting events.", "answer": 1}, {"article": "\u201cHe also had elements of what I know a lot of folks would call \u2018chemo brain.\u2019 He would get very frustrated and very angry, all normal because his little body was just being invaded by this intense medication and rounds of chemotherapy treatment.\u201d Throughout that year, Riddle and her son traveled back and forth from Colorado to Utah, so he could continue chemo, but this time with the aid of cannabis, to make treatment more bearable.\nThe shape of the receptor mirrors the shape of the compound, enabling the CBD to land and attach to the cell.\nShe was willing to do whatever it took to keep him on cannabis.\nBut his mother was now refusing to follow his doctors\u2019 orders.\nBut they are infamously rough for a child and drag on for years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story talks about the availability of marijuana in various states.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the WebMD story, the LA Times story wasn\u2019t clear whether a clinician could conduct the self-hypnosis trainings, or whether the patient needed to find another certified professional. And how were the hypnotic recordings obtained? Readers need to know if their \u201clocal\u201d hypnotherapist can do this.", "answer": 0}, {"article": "The ChemMedChem study is available at http://dx.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\nThe RB analogs inhibited the ATPase activities of two SecA isoforms identified in S. aureus, SaSecA1 and SaSecA2, as well as the SaSecA1-dependent protein-conducting channel.\nBecause of the widespread resistance of bacteria to antibiotics on the market, there is an urgent need for the development of new antimicrobials.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Satisfactory, since we think most readers will come away understanding that there are no currently available treatments based on this approach. But the release doesn\u2019t explicitly establish the lack of availability of such treatments. Nor does it say how far we might be from having such treatments. Had there been some acknowledgment of the fact that this study was done in cell culture and not people, it would have been clearer that such treatments are not available and won\u2019t be any time soon.", "answer": 1}, {"article": "TUESDAY, Oct. 16, 2018 (HealthDay News) -- Stimulating a specific set of nerves that are nestled along the spine may deliver relief to those who suffer from chronic back pain and cut the need for opioid painkillers, new research suggests.\nAlso, the procedure isn't covered by all insurance companies, so out-of-pocket costs to patients can be very high.\n\"In certain patients who have not gotten relief from other treatments, this therapy may give sustained pain relief and may allow them to reduce opioids for at least 18 months and perhaps longer,\" said lead researcher Robert McCarthy.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nThe dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that the device was approved by the FDA in 2016 and its use is confined to \u201cmore advanced medical centers where doctors have been trained in how to implant and regulate the device.\u201d\nAlso, it said the procedure \u201cisn\u2019t covered by all insurance companies, so out-of-pocket costs to patients can be very high,\u201d though it is covered by Medicare.", "answer": 1}, {"article": "William E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\n\u201cThere\u2019s no question that neurofeedback works, that people can change brain activity,\u201d he said.\nDr. Arnold said that if the results bore out that neurofeedback was making the difference, he would seek financing for a broader study, with as many as 100 subjects.\nA major attraction of the technique is the hope that it can help patients avoid drugs, which often have side effects.\nThe brain begins by generating fairly random patterns, while the computer software responds with encouragement whenever the activity meets the target.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that there are 7,500 mental health professionals that offer neurofeedback services.", "answer": 1}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\nAfter adjusting for prognosis and healthy behaviors, the researchers found that patients in the group with the highest levels of vitamin D lived about eight months longer on average than those in the group with the lowest levels.\nIt also took longer for cancer to progress in people with higher vitamin D levels -- an average 12.2 months compared with about 10 months in the group with the lowest.\nHowever, \"if someone has a normal vitamin D level, I wouldn't take supplements to increase it because we won't know the true effect on cancer until we see the results of a clinical trial,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people know that vitamin D supplements are widely available. A brief statement to that effect would have earned the story a satisfactory, as opposed to not applicable.", "answer": 2}, {"article": "In 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nThe study reported at the INS 12th World Congress builds on observations that electrical motor cortex stimulation\u2019s effectiveness in relieving central post-stroke pain can be predicted by rTMS, suggesting the techniques share similar pain-relief mechanisms.\nIt is believed that the stimulation aids in plasticity, the ability of the brain to gradually form new neural connections to take on functions previously performed by damaged areas.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\nHowever, Kobayashi and colleagues point out in their peer-reviewed online publication of this study, \u201cRepetitive Transcranial Magnetic Stimulation Once a Week Induces Sustainable Long-Term Relief of Central Poststroke Pain\u201d (Neuromodulation: Technology at the Neural Interface: April 23, 2015)[1] that there has still been controversy about the efficacy of rTMS in post-stroke pain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "rTMS is commercially available and in widespread use in the US for the treatment of resistant depression. However, the release does not establish that fact, and few patients/consumers would be aware of it. A brief statement about the availability of the device and insurance coverage (none at the moment) would have been helpful for the average reader.", "answer": 0}, {"article": "News releases can also be found at http://www.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nThe cartilage covering the bone surface is not able to heal itself when it is damaged and this is why surgical procedures are available to repair the damaged area.\nThe Sports Ready clinic is student-led under supervision of experienced practitioners, with patients self-referring or sent by private clinics and NHS orthopaedic consultants.\nThe air pressure in the treadmill can be adjusted to take the patient from 100 per cent of their body weight to only 20 per cent, the same feeling as walking on the moon, and reducing the impact and pressure on joints during the run.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not tell us whether the device is available anywhere outside of the specific physical therapy facility profiled in the case study.", "answer": 0}, {"article": "No serious adverse events were reported.\nLONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nFevipiprant, which is being developed by Novartis, reduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients, researchers said on Saturday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We believe the story attempts to give a realistic take, stating more study is needed to show that the drug can reduce severe asthma attacks. It also states Novartis \u201cbelieves the medicine could be filed for regulatory approval in around 2019.\u201d While this may or may not be accurate, it does let readers know that availability isn\u2019t around the corner.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nThe procedure was repeated in 28 patients whose fibroids had not been fully treated, as shown by MRI, and 11 of those patients subsequently got pregnant.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\n\"Women who had been unable to conceive had normal pregnancies after UFE and similar complication rates as the general population in spite of being in a high-risk group.\"\nThe standard treatment option for such women is myomectomy, or surgical removal of the fibroids.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There is no explicit discussion of UFE\u2019s availability, but as conventional UFE is described as such, its availability is implicit.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nThe associated pain can last months or even years.\nThe new study is published in the Journal of the American Medical Association.\nCalled Zostavax, the shingles vaccine is made by Merck.\nAbout a million episodes of shingles, sometimes debilitating, occur in the U.S. annually, Tseng says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that this shingles vaccine has been available in the Untied States since 2006.", "answer": 1}, {"article": "Andersson will be available to the media in an embargoed web briefing on Tuesday, March 7, 2017, at 2 p.m.\nAfter adjusting for cardiovascular risk factors including diabetes, heart failure and stroke, those taking PDE5 inhibitors were found to be markedly less likely to die than those taking alprostadil or no erectile dysfunction drugs.\nThe researchers also were unable to account for socioeconomic status; as a next step, they are planning a larger study that will include more health records and complete information on marital status, educational level and disposable income.\nIt is possible that using erectile dysfunction drugs simply indicates a more active sex life, which could itself contribute to, or be a marker of, a heart-healthy lifestyle overall.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the research was retrospective, it is clear that drugs used to treat ED are available and have been for some time.", "answer": 1}, {"article": "The only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nThe children were given food and drinks totaling the same number of calories, fat, protein and carbohydrates as their typical diets.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\nObese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Bagels and pizza are ubiquitous.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nAfter one year, subjects assigned to SIJ fusion still had significant reductions in pain and disability, as well as improved quality of life.\nThe implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\nThe authors note some important limitations of the trial, including the lack of long-term outcomes in the nonsurgical group due to the high crossover rate.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because the study involved 19 U.S. sites we know there are a number of medical institutions capable of performing the implant. In addition, the release states that the procedure is FDA approved.", "answer": 1}, {"article": "(March 23, 2017)\u2014Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease.\nFind more research highlights in the APS Press Room.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nEstablished in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty obvious that statins are everywhere in America.", "answer": 2}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The two devices mentioned in the story were described as FDA approved, which is true. The story could have made it clear, though,\u00a0that both devices have been in use for a while and that\u00a0off-label use of devices is common. \u00a0", "answer": 1}, {"article": "To book an interview, please contact: \n\nTucker Wilson \n\nMedia Relations \n\nFaculty of Health Sciences \n\nMcMaster University \n\n(905) 525-9140, ext.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nIn a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes no mention of the fact that this vaccine is very far away from a clinical application, assuming it would even pass human trials. Instead, it talks about how easy the vaccine would be to administer and how people wouldn\u2019t even need a lot of training to administer it.\n(We imagine that administering nasal doses to mice would require some training.)", "answer": 0}, {"article": "But there are other theories about how fluoride works.\nIt includes testing the level of bacteria in the mouth, and looking at dietary habits, medical conditions, medications, saliva flow and history of tooth decay.\n\"Some of the stuff in our study has been known for 50 years,\" Evans says, referring to the use of fluoride treatments.\nSome higher-end plans cover two fluoride treatments per year, while cheaper plans tend not to cover any.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the treatments mentioned in the story are widely available, and we were pleased to see the story went a step further and let us know how insurance impacts availability.\n\u00a0", "answer": 1}, {"article": "Among randomized controlled trials (RCTs), there was a statistically significant reduction in CHD risk in higher risk populations, including:\n\u2022 16 percent in those with high triglycerides and 14 percent in those with high LDL cholesterol.\nThe study was supported by a grant from GOED, which played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n\u2022 Be appropriately powered to detect an effect in current clinical conditions.\nCurrent RCTs have varying durations, different baseline CHD status for study participants, and utilize several methods for patient selection and randomization.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers to consuming EPA and DHA in the form of either seafood or supplements, so we\u2019ll give this a pass. However, that single reference to sources of EPA and DHA is only found in a quote in the tenth paragraph.", "answer": 1}, {"article": "\u201cThe key to maximizing protection against colorectal cancer after colonoscopy is performance by an operator with excellent examination\u201d and growth-removal technique, \u201cin a well-prepped colon,\u201d Kahi told Reuters Health by e-mail.\nTumors may simply have gone unidentified on the exam, or were seen but not completely removed.\nHowever, Lieberman cautioned against the over-interpretation of the results.\nAnd for this, patients should do their part.\nBoth groups could do things to improve the detection rate, they said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the screening is widely available and is the standard.", "answer": 1}, {"article": "Kuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nLONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Reuters posted just one reader comment before closing the comment section.\u00a0 It read as follows \u2013 typos and all: \"This is a terrific Leap in Teachnology and should be made available Worldwide at hospitals, clinics and Good Dr. Offices.\" Readers should not have been led to believe the simple, proven breath test is at hand, ready to deploy to doctors. It\u2019s years away if we\u2019re lucky.\n ", "answer": 0}, {"article": "The participants were matched with nine patients within the same age bracket who took standard insulin treatment and 23 healthy non-diabetic people aged 20-64.\nExperts found that the stem cells of patients who took metformin were able to promote the repair of the blood vessels and there was an improvement in how vascular stem cells worked.\nPatients were given metformin at a dose they could tolerate, between one to three tablets a day, for eight weeks.\nThe drug is not regularly given to patients with Type 1 diabetes.\nIt is estimated around 400,000 people in the UK have the condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since metformin is readily available and currently used in treating type 2 diabetes, the release gets a satisfactory rating in this category.", "answer": 1}, {"article": "Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodriguez Jr. T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, DeVore B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Davila-Roman V and Eby CS for the GIFT investigators.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nNow, a new study led by Washington University School of Medicine in St. Louis shows that dosing warfarin (Coumadin and others) is safer -- producing fewer adverse events such as hemorrhage -- when key elements of a patient's genetic makeup are considered.\n\"It's a widely used anticoagulant, but it causes more major adverse events than any other oral drug.\nThe School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The careful reader will get it: testing for these genetic variants is still an experimental practice for the most part, and further testing of how the mutations affect warfarin is needed. But the release could have been more explicit in saying that no one is yet recommending genetic testing for millions of warfarin users.\nWhile the genetic tests are \u201cavailable\u201d in the sense that anyone can order them for the most part, they are not routinely used clinically and probably wouldn\u2019t be covered by insurance so in that sense they are not widely available to most people. ", "answer": 0}, {"article": "For some, relief was almost instantaneous.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the companies are seeking FDA approval of dupilumab and that the agency has given the drug \u201cbreakthrough\u201d status, which allows for expedited development and review. It would have been helpful if the story had acknowledged that this doesn\u2019t necessarily mean \u201cbreakthrough\u201d in the way many people understand the word.", "answer": 1}, {"article": "Rose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nAfter four weeks, seven of those 10 wounds no longer showed the bacteria's presence.\nThe picture has not always been so bright for manuka, or its manufacturers.\nHence the hope that a naturally occurring substance such as honey might help fill the void.\nThe dressings should be available this fall.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that manuka dressings were recently approved by the FDA\u00a0and that the honey can be purchased over the internet.", "answer": 1}, {"article": "Her team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nIn other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\n\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\nThe theory is that exposure to dirt and bacteria early in life--for example, in a dog's fur and on its paws--can create early immunity, though researchers aren't sure whether the effect occurs from bacteria on the furry friends or from human transfer by touching the pets, said Kozyrskyj.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that the availability of dogs in the US is a fact that doesn\u2019t even need to be mentioned. According to the ASPCA, 44% of American households have a dog.", "answer": 2}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\n\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\n\"Overall, it does look like there are at least a couple of genes here, either the mother's genotype or the child's genotype, that show this interaction ... magnifying the size of the effect from not taking the vitamins,\" Hertz-Picciotto says.\nAutism spectrum disorders , marked by impaired language, repetitive behaviors, and social difficulties, now affect up to one in 110 children, according to the CDC.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will know that the vitamins discussed in the story are widely available either by prescription or as over the counter (OTC)\u00a0supplements, so we\u2019ll\u00a0award a satisfactory here.\u00a0However, the story could have been more precise about what exactly these women were taking. Were they using formulations specifically designed for women of childbearing age or\u00a0simply taking a standard multivitamin supplement\u00a0during the prenatal period?\u00a0Did the benefits extend to women who only took folic acid, which\u00a0is widely regarded as the most important vitamin\u00a0to supplement during the prenatal period? In addition, the story\u00a0might have\u00a0noted that there\u00a0are different formulations of prenatal vitamins with varying doses of\u00a0key nutrients. It would have been helpful to include some discussion of\u00a0the nutrients women\u00a0should look for and why.", "answer": 1}, {"article": "The study published online May 16 in Circulation: Arrhythmia and Electrophysiology.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\n\"Based on that, the study may provide more certainty in terms of cost-effectiveness.\"\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not say that the FDA approved the device last year, or how widely available it is.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article reported on what it terms \u2018the first human testing\u2019 of vaccine against the bird flu. While mentioning other studies underway, and not explicitly stating that this vaccine is not currently available to the public, a thread throughout the piece made it clear that vaccine against this strain of flu was still a work in progress.", "answer": 1}, {"article": "Scientists have also found impulsive behaviour is a factor in leading to food addiction and Ivo Vlaev, of Warwick Business School, plus Myutan Kulendran, Laura Wingfield, Colin Sugden, and Ara Darzi, of Imperial College London, discovered that a drug called Modafinil, usually used for narcolepsy, shift work disorder and excessive daytime sleepiness, can reduce impulsivity and thus food addiction.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n\"We found Modafinil, which is already on the market, did reduce people's impulsive behaviour,\" said Professor Vlaev.\nFood addicts suffer from the same neurobiological conditions so we believe it will help food addicts as well and our initial tests have backed up that theory.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that modafinil is already on the market and widely available around the world.", "answer": 1}, {"article": "Flublok is the only flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective (see Skowronski et al.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\nFDA approved the quadrivalent formulation (\"Flublok Quadrivalent\") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\nFlublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explicitly states that: \u201cFlublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season.\u201d", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nThe findings are published in TheJournal of the American Medical Association.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that both GeneSight from Myriad Genetics, and Genecept from Genomind, are commercially available.", "answer": 1}, {"article": "So researchers have been looking for alternatives.\nThe study, of 205 women, found that those randomly assigned to take Lexapro (escitalopram) for eight weeks reported less daily \u201cinterference\u201d from their hot flashes.\nIn fact, Freedman said, there\u2019s some evidence that lowering serotonin levels does not worsen hot flashes \u2014 which would be expected if the \u201cserotonin theory\u201d is correct.\n\u201cOverall, the picture is not optimistic.\u201d\n\nIn his own study last year, Freedman used a different approach to measuring hot flashes: instead of asking women to record their symptoms in a diary, the researchers had them wear a \u201cdetector\u201d to monitor objective measures of hot flashes.\nAnd studies have suggested that a few antidepressants, used at low doses, can be helpful for some women \u2014 including paroxetine (Paxil), fluoxetine (Prozac) and venlafaxine (Effexor).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article made it clear that the use of antidepressants to treat hot flashes was off-label use of the drug. \u00a0Even though the article presented results from studies, it is not clear how widespread is the off-label use of antidepressants to treat hot flashes.", "answer": 1}]